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Liquid biopsy is the sampling and analysis of analytes from various biological 
fluids to detect and diagnose cancer, for which it is an alternative to solid tissue 
biopsy for the detection of cancer. Compared to solid tissue biopsy, liquid 
biopsy is minimally invasive. Further, its ability to capture intra-tumoural and 
inter-metastatic heterogeneity in cancer makes it an attractive platform to 
complement solid tissue biopsy. Molecules of free circulating DNA in the 
bloodstream, termed cell-free DNA (cfDNA), can be used as an analyte for 
liquid biopsy. Various types of tumour-specific alterations can be detected in 
the cfDNA of cancer patients. To date, liquid biopsy assays based on the 
analysis of cfDNA are still lacking in consistency and precision. Clinical validity 
and utility have not been shown for the majority of assays. The composition of 
cfDNA in health and under particular physiological and pathological conditions 
still need to be better understood. Further improvements to diagnostic tools 
are required to enable detection of small numbers of molecules for liquid 
biopsy. Animal models may be useful as a platform to study cfDNA and cancer 
biology in liquid biopsy. The utilisation of an animal model may spare ethically 
sensitive clinical materials from patients and serve as an alternative when 
serial sampling from patients is challenging. For cancer biology, experiments 
in animal models are required to understand the mechanisms underlying the 
onset of malignancies and to identify methods to prevent, diagnose and treat 
diseases. In this PhD thesis, the tissue origins of cfDNA were investigated 
using tissue-specific reporter mouse models. Liver injury was induced in mice 
to investigate the effect of tissue injury on the composition of cfDNA. In addition, 
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the potential of the analyses of cfDNA as a biomarker of tissue injury in 
paracetamol (APAP) overdose patients was investigated. Absolute 
measurement of the tissue origins of cfDNA using ddPCR showed that myeloid, 
lymphoid and erythroid cells were major tissue contributors to cfDNA, adding 
up to ~78% of cfDNA pool in healthy tissue-specific reporter mice. A minor 
contribution was observed from hepatocytes (4.2%). No contribution was 
detected from muscle cells. Up to ~17.6% of contribution was unaccounted, 
indicating contribution of other tissues not studied in this project. Following 
APAP overdose in mice, total concentration of cfDNA increased by ~100-fold 
and the contribution of hepatocytes increased by ~20-fold. Similarly, a 
substantial increase in total cfDNA and liver-derived cfDNA was also observed 
in clinical samples from APAP overdose patients, highlighting the potential of 
the analyses of cfDNA as a biomarker of tissue injury in APAP overdose 
patients. In separate experiments, genomic analysis was performed on the 
cancer genome of the Pirc rat, a mutant rat of colorectal cancer (CRC), to 
screen for potential candidate biomarkers for liquid biopsy. Genomic analysis 
in the cancer genome of the Pirc rat showed candidate LOH biomarkers in 
chromosome 18, along with other types of somatic alterations in relevant 
cancer genes. These are potential markers of cancer development in future 
cfDNA studies in the Pirc rat. To conclude, successful analyses in rodent 
models showed the tissue origins of cfDNA in the healthy state and following 






Liquid biopsy involves sampling and analysing substances from biological 
fluids to detect cancer. It is an alternative to invasive sampling from solid tissue 
for the detection of cancer, termed solid tissue biopsy. Compared to solid 
tissue biopsy, liquid biopsy is less invasive or harmful. Further, it is an attractive 
platform to complement solid tissue biopsy because it can capture variability 
within a tumour and variability within different tumours at different locations in 
the body. A DNA substance circulating freely in the bloodstream, called cell-
free DNA (cfDNA), can be used for analysis in liquid biopsy. Many types of 
tumour-related DNA changes can be detected in cfDNA of cancer patients. To 
date, liquid biopsy tests based on the analysis of cfDNA are still lacking in 
consistency and precision. The extent of how well the tests can detect the 
presence or absence of diseases, and whether the tests provide clinically 
useful information, such as for diagnosis, treatment, management or 
prevention of diseases, have been incompletely demonstrated for the majority 
of liquid biopsy tests. The composition of cfDNA in healthy and other diseased 
conditions needs to be understood for optimal utility of the liquid biopsy 
approach. Animal models can be used to study cfDNA and the biology of 
cancer for liquid biopsy. The utilisation of animal model may spare ethically 
sensitive clinical materials from patients and serve as an alternative when 
repeated sampling from patients is challenging. For cancer biology, 
experiments in animal models are essential to understand the mechanisms 
underlying the beginning of cancer and to discover methods to prevent, 
diagnose and treat diseases. In this PhD thesis, the contribution of various 
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tissues that constitute cfDNA was investigated using healthy tissue-specific 
reporter mouse models. Tissue-specific reporter mouse models are mouse 
models with specific DNA alterations in tissues of interest. Liver injury was 
induced in mice to investigate the effect of tissue injury to the composition of 
cfDNA. Further, the potential of the analyses of cfDNA to detect tissue injury 
in paracetamol (APAP) overdose patients was investigated. Analysis of the 
contribution of different tissues to cfDNA in tissue-specific reporter mouse 
models using a state-of-the-art platform, called the ddPCR, showed that blood 
cells, which include myeloid, lymphoid, and erythroid cells, were major 
contributors to the composition of cfDNA, adding up to ~78% of the circulating 
cfDNA in the healthy state. Hepatocytes, a major component of the liver tissue, 
contributed around 4.2% to cfDNA in the healthy state. Muscle cell 
contributions were undetected. Up to ~17.6% of contribution was unaccounted, 
indicating likely contribution of other tissues not studied in this project. 
Following APAP overdose in mice, total concentration of cfDNA increased by 
~100-fold and the contribution of hepatocytes increased by ~20-fold. This 
similar increase was observed in clinical samples from APAP overdose 
patients, highlighting the potential of the analyses of cfDNA as a biomarker of 
tissue injury in APAP overdose patients. Additionally, the analysis of whole 
DNA sequences, termed whole genome sequencing analysis, was performed 
in the tumour of large intestine from a genetically modified rat model of large 
intestinal cancer, called the Pirc rat. This analysis was performed to look for 
potential candidate changes in DNA to be used in liquid biopsy. Whole genome 
analysis of large intestinal tumours of the Pirc rat showed a large structural 
 vii 
alteration in DNA sequences, called the LOH in chromosome number 18, 
along with other types of tumour-specific changes in previously reported 
relevant cancer genes in human. This LOH alteration in cancer of the large 
intestine may serve as a potential alteration to be analysed in cfDNA for liquid 
biopsy. To conclude, this study successfully utilised mouse and rat models to 
investigate the tissue origins of cfDNA in the healthy state and following APAP 
overdose, as well as revealed potential biomarkers of colorectal cancer for 
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Chapter 1 Introduction 
 
1.1 Liquid biopsy: non-invasive detection of cancer 
 
Liquid biopsy is the sampling and analysis of analytes from various biological 
fluids to detect and diagnose cancer, a disorder characterised by abnormal 
and uncontrolled cell growth. It serves as an alternative to solid tissue biopsy, 
an invasive extraction of solid tissue to detect cancer that is risky, painful and, 
in some cases, unavailable [1, 2]. Analytes in liquid biopsy include circulating 
tumour cells (CTCs), circulating cell-free DNA (cfDNA) and RNA (cfRNA), 
extracellular vesicles, proteins and other metabolites [1]. These analytes are 
derived predominantly from blood but also other accessible fluids, such as 
cerebrospinal fluid (CSF), urine, ascites fluid [1, 3]. 
The gold standard method for genetic profiling of cancer is tissue biopsy [4]. It 
provides morphological information of the tumour and has high diagnostic 
certainty [3]. However, due to its invasive nature, tissue biopsy imposes higher 
risk to patients compared to liquid biopsy. Moreover, tissue biopsy may fail to 
capture the heterogeneity of cancer within a tumour tissue and between 
tumours at different locations, thus affecting the accuracy of the test [4]. 
Together, tissue and liquid biopsy complement each other and provide the 
highest diagnostic standard for cancer patients [3]. 
More studies are required to show the potential of cancer liquid biopsy and 
overcome its limitations [3]. The clinical applications of liquid biopsy potentially 
include detection and localisation of neoplastic growth, prediction of tumour 
stage and prognosis, genotyping of tumour and identification of potential 
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targeted therapeutics, monitoring treatment efficacy and resistance, as well as 
identification of early-stage recurrence [5]. Despite these potential applications, 
liquid biopsy assays are currently still lacking in consistency and precision. 
Clinical validity and utility have not been shown for the majority of assays. The 
composition of cfDNA analytes in health and under particular physiological and 
pathological conditions need to be better understood. Finally, further 
improvements to diagnostic tools are required to enable detection of small 
amounts of molecules for liquid biopsy [1].  
 
1.2 Definition and classifications of biomarkers 
 
Understanding different types of biomarkers is important to discuss liquid 
biopsy approaches in details [2]. A biomarker is an objectively measured 
characteristic that describes a normal or abnormal state in an organism by 
analysing biomolecules such as DNA, RNA, protein, peptide and chemical 
modifications of biomolecules. The World Health Organisation (WHO) defined 
a biomarker as any substance, structure or process that can be measured in 
the body or its product and influence or predict the incidence or outcome of 
diseases. A cancer biomarker may measure the risk of developing cancer in a 
specific tissue or, alternatively, may measure the risk of cancer progression or 
potential response to therapy. Biomarkers play an important role in the clinical 
management of cancer patients [6]. 
Cancer biomarkers can be classified into three categories based on their utility. 
Predictive biomarkers predict response to specific therapeutic interventions. 
Prognostic biomarkers may not be linked to therapeutic decisions but aim to 
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inform clinicians about the risk of clinical outcomes such as cancer recurrence 
or disease progressions in the future. Diagnostic biomarkers identify whether 
a patient has a specific disease condition [6]. 
 
1.2.1 Types of DNA alterations used as biomarkers 
 
Different types of alterations in DNA may be used as a biomarker of cancer. 
This may include alterations in nucleotide sequence of DNA, termed mutations, 
or other modifications in DNA, including CpG dinucleotide methylation 
changes [7, 8].  
A mutation can be distinguished into two categories based on its location in 
the body: germline and somatic mutations. A germline mutation occurs in the 
germ line, tissue that forms reproductive cells during the course of 
development. A germline mutation may be passed onto some or all individuals 
of the next generation. A somatic mutation occurs in a single cell or a 
population of cells in developing somatic tissue and cannot be transmitted onto 
individuals of the next generation [9]. 
Based on the types of alterations on DNA sequences, a mutation can be 
classified into point mutations and small deletions, as well as chromosomal 
abnormalities (Figure 1.2.1). A missense mutation involves a change in a 
single nucleotide (also called single nucleotide variants, SNV). A nonsense 
mutation is a change in nucleotide bases that changes the amino acid into stop 
signal in protein-coding genomic DNA (gDNA) sequence. A frameshift 
mutation can be caused by additions or deletions of nucleotides that changes 
the reading frame in which DNA is translated. Chromosomal abnormalities 
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include large structural changes, such as inversion, duplication, deletion, 
translocation and insertion [10].  
 
 
Figure 1.2.1 Types of mutations. 
The types of mutation can be classified into point and small deletions, as well as chromosomal 
abnormalities. (a) point mutation and small deletions typically affect the function of only one 
gene. (b) Chromosomal abnormalities affect large segments of DNA. Illustration taken from 
[10]. 
 
DNA methylation is a modification of DNA base by the addition of a methyl 
group by DNA methyltransferase enzymes. This modification predominantly 
occurs at CpG dinucleotides sequences in mammalian cells. The levels of 
DNA methylation at individual CpG site as well as the distribution of methylated 
and unmethylated CpGs are linked to development state and cellular 
differentiation [11], leading to specific profiles of methylation pattern in different 
tissues of mammalian organisms [12]. Perturbation of CpG dinucleotide 
methylation may lead to changes in gene expression or genomic instability and 
lead to cancer [11].  
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Analysis of CpG dinucleotide methylation may be performed following a 
bisulphite conversion procedure. This procedure converts unmethylated 
cytosine bases into uracils, while leaving methylated cytosines as cytosines. 
Changes in this DNA sequence can then be detected by a variety of 
subsequent analyses, such as sequencing. The bisulphite conversion 
procedure may degrade a significant amount of DNA, up to 95%. Therefore, 
multiple factors, including DNA input amount, are controlled to optimise 
conversion and reduce loss of DNA [8]. 
For the detection of cancer, analyses of different types of tumour-specific 
alterations come with different advantages. Analyses of somatic mutations in 
liquid biopsy may offer high specificity because these alterations are present 
only in genomes of cancer or pre-cancerous cells and not in DNA of normal 
cells of the same individuals [13]. On the other hand, analyses of epigenetic 
alterations and nucleosomal mappings in cfDNA may show the presence of 
tumour and locate its tissue of origin [1, 14, 15]. 
 
1.3 Cell-free DNA: an analyte in liquid biopsy 
 
The presence of DNA circulating in human plasma was first described in 1948 
[16]. These molecules are termed cell-free DNA (cfDNA). Aside from the 
plasma, cfDNA can also be isolated from other biological fluids such as urine, 
CSF, and ascites fluid [17]. In the plasma, a proportion of cfDNA circulates as 
nucleosome or chromatosomes, nucleosome that are bound to histone H1 
protein, and another as free DNA [14, 17]. The size of cfDNA from healthy cells 
is postulated to be between 160 and 200bp [18, 19] with different estimates 
between methodologies including XXX and YYY. For example, using high 
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throughput sequencing, the size of cfDNA is on average of 167bp, originating 
from approximately 147bp from nucleosome and 20bp linker histone [14]. 
cfDNA that originates from tumour in cancer patients and foetus in the 
circulation of pregnant women is on average shorter than cfDNA from healthy 
cells [18, 20, 21]. 
cfDNA is thought to be released by cells into biological fluids by a mixture of 
cellular breakdown mechanisms, such as apoptosis and necrosis, as well as 
active DNA release mechanism from living cells [17, 19, 22]. Studies suggest 
that apoptosis is the main mechanisms of cfDNA release in both healthy and 
diseased states [19]. This is supported by the fact that cfDNA fragments 
consisted of a ladder pattern of 180-200bp or multiples thereof when analysed 
using DNA electrophoresis and sequencing [18, 19]. 
Analysis of the tissue origins of cfDNA in human has indicated that cfDNA 
originates predominantly from apoptosis of hematopoietic cells [14, 23, 24], 
with minimal contribution from other tissues, such as liver [25] and endothelial 
cells [26]. The circulation of cancer patients may contain cfDNA that derives 
from tumours, termed circulating tumour DNA (ctDNA) (Figure 1.3.1). The 
proportion of ctDNA in the circulation of cancer patients varies depending on 
types of tumour and tumour burden [1, 22]. The circulation of pregnant women 







Figure 1.3.1 The circulation of a cancer patient contains cfDNA from healthy and tumour 
cells. 
In the circulation of a cancer patients, DNA is released by healthy cells (shown in blue) and 
tumour cells (shown in green), mainly through cellular death mechanisms. DNA from tumour 
cells, ctDNA may contain tumour-associated alterations, including point mutations and 
structural variations. Illustration taken from [22]. 
 
1.3.1 Applications of the analysis of cfDNA in other human 
diseases 
 
The presence of tumour DNA in the circulation of cancer patients [28], and 
foetal DNA in the circulation of pregnant women [27] formed the basis for the 
two main applications of the analysis of cfDNA: in the detection of cancer and 
foetal abnormalities. The detection of foetal abnormalities using the analysis 
of cfDNA is termed non-invasive prenatal testing (NIPT). NIPT is an alternative 
to invasive prenatal testing that includes an invasive amniotic fluid sampling 
that poses a risk of miscarriage [29]. NIPT is now routinely used in the clinic 
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for detection of foetal aneuploidy, mainly for the detection of trisomy 13, 18 
and 21 [29, 30]. Proof-of-concepts experiments for further development of 
NIPT are currently ongoing. This include the analysis of whole foetal genome, 
methylome and transcriptome [29]. 
Other than cancer liquid biopsy and NIPT, there are other potential 
applications of the analysis of cfDNA, such as tissue health in solid organ 
transplantation [31] and other internal tissue injury [32, 33]. For monitoring on 
the health in solid organ transplantation, the analysis of cfDNA is an alternative 
to donor organ biopsy. Donor organ biopsy is typically performed in response 
to suspicion of graft pathology or as a part of a routine monitoring protocol. 
Proof-of-concepts experiments for monitoring on tissue health in solid organ 
transplantation have been shown for various tissues, including kidney, liver, 
heart, pancreas and lung [31]. The applications of the analysis of cfDNA for 
other internal tissue injury have been shown for injury in brain following 
traumatic brain injury, pancreas following pancreatitis, and heart following 
myocardial infarction [32, 33]. 
 
1.3.2 Current limitations of the analysis of cfDNA 
 
Currently, both physiological and technical factors are limiting the 
implementation of cancer liquid biopsy based on the analysis of cfDNA in the 
clinic. The composition of cfDNA in healthy individuals and how it changes 
during physiological processes are not well understood [1]. Knowledge of 
biological factors and mechanisms that influence the size distribution of cfDNA 
are still limited [20]. Plasma often contains only low levels of cfDNA. This limits 
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the number of input molecules, types of tumour-specific alterations to be 
analysed and, particularly, affects the detection of mutant DNA fragments with 
low of variant allele fractions. Finally, the implementation of cfDNA is still 
limited by technical limitation of analytical limit of detection of different methods 
being used [1].   
 
1.4 Development of technologies in liquid biopsy 
 
A liquid biopsy test consists of three distinct phases, including the pre-
analytical, analytical and post-analytical phase. The pre-analytical phase of 
liquid biopsy testing includes the collection, transport and pre-processing of 
samples. The analytical phase comprises of the laboratory testing of samples 
with the selected methods. The post-analytical phase consists of data analysis, 
interpretation and reporting. A standardised and optimised analytical workflow 
is important to allow for robust and reproducible cfDNA analysis  [34]. This 
section describes advances made in these three phases of testing in cancer 
liquid biopsy, specifically using cfDNA. 
 
1.4.1 Advances in pre-analytical methodologies of cfDNA 
analysis 
 
Variations in pre-analytical processing of samples significantly affect results of 
cfDNA analysis. Optimal and standardised sample pre-processing methods 
are important to minimise lysis of peripheral blood cells prior to cfDNA analysis  
[35]. Pre-analytical considerations of cfDNA samples include sample sources 
of cfDNA, blood collection and preservation, cfDNA isolation and storage [36]. 
cfDNA can be obtained mainly from either plasma or serum samples.  
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The choice between serum and plasma as the optimal sampling specimen is 
controversial [7]. Measurement of total cfDNA showed that serum samples 
contained more cfDNA than plasma samples. Further, estimation of total 
amounts of telomeres shows significantly higher amount in cfDNA from serum 
compared to plasma [37]. Analysis of DNA fragment size showed that cfDNA 
from serum samples has larger numbers of longer fragments of cfDNA than 
from plasma samples. This suggested the occurrence of lysis of leukocytes in 
cfDNA from serum samples during sample processing. However, serum 
samples are still a useful source of cfDNA. A study showed that there is no 
significant difference in terms of sensitivity and specificity of cfDNA analysis 
from serum or plasma samples for cancer detection [38]. 
The concentrations of extracted cfDNA are affected by different technical 
factors, such as anticoagulants, blood collection tubes and the time of delay 
between blood draw and centrifugation. The total concentration of cfDNA 
increase overtime prior to centrifugation in EDTA-stabilised blood. Specialised 
blood collection tubes, such as cell-free DNA BCT (Streck) and PAXgene 
blood DNA tube (Qiagen) contain anticoagulants that prevent lysis of blood 
cells for several days at room temperature [38]. It is recommended to use 
specialised blood collection tubes, or in case of EDTA tubes, process cfDNA 
within 2 to 6 hours of blood collection to prevent the release of gDNA from 
leukocytes [36]. 
The majority of studies utilise a single centrifugation or double centrifugation 
steps to separate plasma or serum from blood samples. The majority of these 
studies showed that there is no significant difference in between a single and 
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double centrifugation steps to DNA yield [38]. However, a single study 
suggested that a double centrifugation protocol may be better in removing 
contaminating nuclear DNA than single centrifugation step [39]. A double 
centrifugation protocol is recommended to allow for complete separation of 
cellular fractions and avoid mechanical lysis of leukocytes [36]. 
There is an effect of storage temperature to the concentrations of extracted 
cfDNA in EDTA-stabilised blood when processed within 6 hour [38]. The 
concentrations of cfDNA are not affected for 2 weeks when plasma samples 
are stored in -80°C. But a significant decrease is shown when plasma samples 
are stored in more than 37°C [40]. It is recommended to freeze plasma 
samples at -20 or -80°C, not store plasma samples at 2-8°C for longer than 24 
hour, and avoid frequent freeze thaw cycles to prevent increased 
fragmentation and reduced cfDNA yield [36]. 
Methods of cfDNA extraction vary between in house protocols, such as phenol 
chloroform extraction [41] and different commercially available kits [38]. The 
majority of cfDNA extraction protocols are either column- or magnet-based. 
The most commonly used commercial kit is the QIAamp circulating nucleic 
acid (Qiagen). This kit has been reported to produce high cfDNA yield. An 
automated extraction protocol is advantageous to minimise hands-on time and 
aid in standardisation [42]. 
 
1.4.2 Advances in analytical methodologies of cfDNA analysis 
 
Early advances in cfDNA analyses for liquid biopsy was focused on simple 
assessment of cfDNA concentration in the circulation [43]. The low 
concentration of cfDNA extracted from plasma makes quantification using 
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spectroscopy and fluorometry problematic.  Quantitative PCR (qPCR) assays 
are more frequently used for measurements of total cfDNA [44]. Total 
concentration of cfDNA can be quantified using a single-locus qPCR [45], or 
qPCR of repeat DNA sequences, such as qPCR of ALU sequences [46]. The 
size of cfDNA fragments can be analysed using DNA fragment analyser, qPCR, 
or more accurately using next-generation sequencing [20, 47]. These simple 
methodologies for the assessment of cfDNA have a limited utility for detection 
of cancer. This in turn leads to the development of specific approaches for the 
analysis of cfDNA for cancer detection [43]. 
There are two main approaches in analysis of cfDNA for detection of cancer. 
A targeted approach includes the analysis of known tumour-specific alterations. 
The alteration may be a frequently occurring driver mutation with implications 
for therapeutic decision. An untargeted approach does not require knowledge 
of any specific alteration associated with tumours. An untargeted approach is 
often used to discover novel tumour-specific alterations and useful for 
detection of molecular resistance as well as identification of new therapeutic 
targets [43]. 
Development of methodologies for targeted analysis of cfDNA has allowed for 
identification of mutant alleles at very low frequencies, down to 0.02%. These 
methodologies include amplification refractory mutation system (ARMS), 
beads emulsions amplification and magnetics (BEAMing), droplet digital PCR 
(ddPCR), as well as personalised panel for cancer profiling, such as cancer 
personalised profiling by deep sequencing (CAPP-Seq) and tagged-amplicon 
deep sequencing (TAm-Seq) [43, 48, 49]. ARMS is a simple method for 
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detecting mutations involving small base changes or deletions. It utilised 
sequence-specific PCR primers that only amplifies DNA when the target allele 
is present [50]. BEAMing and ddPCR utilise magnetic and droplet emulsion 
partitioning, respectively, to perform single molecule amplification, with ddCPR 
(Figure 1.4.2.1) being the major method to detect genomic alterations in 
cfDNA [51, 52]. Analyses of cfDNA with personalised panel combines a 
multiphase bioinformatics approach to identify targets, an optimised library 
preparation methods, and sequencing at a deep coverage [43].  
 
 
Figure 1.4.2.1.4.1 Workflow of ddPCR. 
DNA template is extracted from virus, tumour or blood. Following extraction, DNA template is 
mixed with PCR reaction mix and partitioned randomly into individual droplets of approximately 
20000 droplets. Amplification reaction is performed with double-stranded DNA dye EvaGreen 
or hydrolysis probe. Fluorescent signal from each individual droplet is read after amplification, 
giving positive or negative signal. Illustration taken from [52]. 
 
Unlike targeted approach, genome-wide analyses of liquid biopsy are 
applicable to all patients because these analyses do not rely on recurrent 
genetic alterations. Further, genome-wide analyses are able to detect not only 
small alterations, but also tumour-associated copy number alterations. 
Examples of methodologies in this approach include array-based comparative 
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genomic hybridisation (array-CGH), whole exome sequencing (WES) and 
whole genome sequencing (WGS). These methodologies are less cost-
effective than targeted methodologies. However, with the reduction of 
sequencing costs and improvement of turnaround time, as well as emergence 
of novel sequencing technologies with improved accuracy, this approach will 
eventually be widely available for clinical purposes [43].    
The sensitivity of both targeted and whole-genome approach for the detection 
of cancer is affected by low abundance of ctDNA within an excess of 
background cfDNA originating from healthy cells. To overcome this challenge, 
methodologies have been developed to allow for enrichment of ctDNA by 
removing excess background cfDNA from healthy cells, such as nuclease-
assisted minor-allele enrichment using overlapping probe (NaME-PrO) 
(Figure 1.4.2.2) and methylation-specific nuclease-assisted minor allele 
enrichment (MS-NaME), for detection of somatic mutation and tumour-
associated CpG dinucleotide methylation changes respectively. Both 
technologies utilise probes that specifically bind to background cfDNA, but not 
fully bind to ctDNA due to mismatches from somatic mutations or methylation 
changes. A duplex-specific nuclease digests dsDNA, resulting in enrichment 





Figure 1.4.2.2 Components and workflow of NaME-Pro. 
(A) Components of NaME-Pro consists of specific probes that bind to bottom and top strands 
of wildtype DNA, and a duplex-specific nuclease. (B) Probes hybridise to target region of 10-
15bp in length. This overlapping region defines the target DNA region to be enriched. (C) The 
workflow of NaME-Pro consisted of denaturation and incubation of DNA with NaME-Pro 
components at ~67°C. Illustration taken from [53]. 
 
1.4.3 Advances in post-analytical methodologies of cfDNA 
analysis 
 
The advancement of technologies and bioinformatics algorithm for the analysis 
of cfDNA in liquid biopsy is rapid. This is supported by the maturation of 
massively parallel sequencing technologies that allows for the characterisation 
of cfDNA at a single base resolution and genome-wide scale [55]. Best 
practices workflow for algorithms of data pre-processing and discovery of 
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somatic short variants, such as single nucleotide variants and small indels, are 
now available [56–58]. Recent advances in bioinformatics also allow for 
estimation of ctDNA fraction in cfDNA, non-invasive detection of copy number 
aberrations, genomic rearrangements and methylation analysis for the 
detection of cancer [55]. 
A number of tools for analysis of variant discovery from the cancer genome is 
now widely available (Figure 1.4.3.1) [59]. Raw sequence data is typically 
aligned to reference genome using alignment tools, such as Burrows-Wheeler 
Aligner (BWA) [58], to produce alignment files (BAM files). Several algorithms 
are then available to call somatic variants from alignment files. Most of these 
tools compare variant allele fraction in the cancer genome with paired normal 
genome. Different tools are utilised to discover different types of somatic 
variants, such as single nucleotide variants (SNVs), short indels variants, 
structural variants (SVs) and copy number variants (CNVs). These variant 
callers produce vcf files containing a list of discovered variants. Variants can 




Figure 1.4.3.1 A general workflow and representative sets of tools for the analysis of 
cancer genome sequencing. 
Raw sequence data is aligned to generate BAM alignment files. PCR duplicates are removed 
from BAM files prior to different types of somatic variant calling, such as SNV, short indels, SV 
and copy number analysis. Variants are annotated and interpreted. Illustration taken from [59]. 
 
Accurate estimation of ctDNA within the background of cfDNA from healthy 
cells has proved challenging. The fraction of ctDNA in cfDNA may be 
estimated by conventional PCR amplification of multiple oncogenes. However, 
the heterogeneity of tumour cells complicates PCR based estimation of ctDNA 
fraction. For example, some variants are only present in subclones of a tumour, 
so that lower fractions of these variants are present in the circulation, leading 
to inaccurate estimation of ctDNA fraction. Estimation of ctDNA fraction can 
be analysed using two bioinformatics approaches in massively parallel 
sequencing data: the mutant allele approach and the loss-of-heterozygosity 
(LOH) approach. The mutant allele approach utilises a predetermined set of 
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mutations commonly found in certain cancers or found in matching tumour 
samples. The mutant allele fraction can be expressed as the number of 
sequencing reads containing mutant reads over total alleles. The LOH 
approach takes the advantage of the presence of LOH in tumours. Sequencing 
reads carrying heterozygous single nucleotide variants reflect non-tumour 
fraction of cfDNA, whereas reads carrying LOH variants reflect ctDNA [55]. 
Non-invasive detection of copy number variants in cfDNA may serve as a 
promising cancer detection biomarker because copy number aberrations can 
be found in almost all tumours. There are two main approaches for detection 
of copy number variants in sequence data. The first approach divides the 
genome into equally sized bins, and estimates copy number gains or losses 
by the increase or decrease of genomic representation in cfDNA. The other 
approach examines aberrant changes in chromosomal arms. The bin 
approach is more generalised and can be applied to all cancer, whereas the 
chromosomal arms approach can only be applied to cancer types that primarily 
affect chromosomal arms, such as breast and colon cancer [55]. 
As with copy number aberrations, genomic rearrangements, such as BCR-ABL 
fusion in chronic myeloid leukaemia, is common in many cancer types. The 
detection of gene fusion in cfDNA utilises mate-pair library sequencing to 
identify reads containing genomic rearrangement breakpoints. These 
breakpoints can be validated by designing PCR assays across the breakpoints. 
Detection of genomic rearrangements has been shown to be specific for 
cancer patients, however, it requires high sequencing depth [55]. 
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Finally, advances have been made in the analysis of DNA methylation in 
cfDNA. CpG dinucleotide methylation can be analysed in cfDNA by treating 
DNA with sodium bisulphite. This converts unmethylated cytosines into uracils 
while leaving methylated cytosines unchanged. PCR amplification can be 
performed using primer-pairs specific for bisulphite-converted DNA. 
Amplification of bisulphite-converted DNA will convert uracils into thymines, 
whereas methylated cytosines will remain as cytosines. Sequencing of 
bisulphite converted DNA and comparison of its results to original DNA 
sequence would reveal the methylation status. During bisulphite sequencing, 
unmethylated cytosines are sequenced as thymines, whereas methylated 
cytosines are read as cytosines. The presence of cytosines indicates the 
presence of methylation in the original DNA sample. Multiple bisulphite 
sequencing alignment tools, such as Bismark and BSmooth, are now available 
[55, 60–62].  
Aside from DNA bisulphite conversion, amplification and sequencing, 
methylation status can be shown by other methods. Profiling of methylation 
status across whole genome can be performed by chromatography. 
Separation of methylated cytosines from other components of hydrolysed DNA 
and measurement of its fraction can show global levels of methylation across 
the whole genome. Global methylation status can also be shown using 
enzyme-linked immunosorbent assay (ELISA), using antibody specific for 
methylated cytosines. Detection of the methylation status of specific fragments 
of DNA may also be performed using methylation-specific fingerprinting 
methods, such as amplification fragment length polymorphism (AFLP) and 
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restriction fragment length polymorphism (RFLP). Detection of methylation 
status across the genome can be performed using hybridisation array as an 
alternative to bisulphite sequencing, or bisulphite sequencing following 
enrichment using methyl-binding proteins or antibody immunoprecipitation [63].  
 
1.5 The role of rodent models in liquid biopsy 
 
Genetically modified animals are organisms in which specific genes have been 
altered to create models for human and animal diseases. A transgenic model 
is defined as an animal that carried one or more foreign gene, deliberately 
through insertion into the animal’s genome. The foreign gene is constructed 
using recombinant DNA technology. In cancer, control of oncogenes and 
tumour suppressor genes can be controlled spatial and temporally in animal 
models using tissue-specific and inducible expression of Cre-loxP 
recombination system (Figure 1.5.1), a bacteriophage P1 site-specific 
recombination system that enables excision of DNA fragments between two 






Figure 1.5.1 Mechanism and breeding strategy of Cre-loxP recombination system. 
(A) Mechanism of Cre-loxP system. Cre recombinase (38kDa) recognises loxP sequences 
and facilitates excision of gene Y, that is flanked in between the two loxP sites, leaving one 
loxP site following recombination. (B) Mouse carrying Cre recombinase allele under a specific 
promoter X is bred with mouse carrying target alleles between two loxP sites (floxed alleles). 
The litter (F1) may inherit both Cre recombinase gene and target alleles, resulting in 
inactivation of target gene Y in a specific tissue X. Illustration taken from [66].  
 
The mouse is the most common model organism for preclinical studies. Mouse 
models have many advantages over other model organism. A comparison 
between mouse and human genome showed that mouse shares a majority of 
its protein-coding genes with human [67], with 40% similarity at  DNA 
sequence level to the human genome [68]. Genetic and molecular tools are 
available for modification of the mouse genome. The small animal size 
facilitates study for larger numbers making it a cost-efficient model [65]. 
Similarly to mouse models, resources for the genetic manipulation of rat 
models are now available [69].  Rat models offer the advantage of easier 
monitoring of physiology and ability to perform of surgical procedures. 
Additionally, rats are more intelligent than mice and capable of learning a wider 
variety of tasks important to cognitive research. The choice between mouse or 
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rat model for studying a particular condition would be specifically depend on 
which model is more biologically appropriate [70].  
There are advantages of animal models as alternative platform to study cfDNA 
and cancer biology in liquid biopsy. Animal models can be used to optimised 
liquid biopsy approaches and spare ethically sensitive clinical materials from 
patients [71]. Studies in animal models can serve as an alternative when serial 
sampling from patients is challenging [72]. For cancer biology, experiments in 
animal model is essential to understand fundamental mechanisms underlying 
the onset of malignancies and to discover methods to prevent, diagnose and 
treat diseases [65]. 
 
1.6 Thesis aims 
 
In this PhD project, genomic analyses were performed on rodent models to 
study the tissue of origins of cfDNA and the genomic landscape of colorectal 
cancer (CRC) (Figure 1.6.1).  
• Chapter 3 aimed to establish and utilise tissue-specific reporter mouse 
models in investigating the tissue origins of cfDNA in the healthy state. 
In this chapter, assays for absolute quantification of the tissue origins 
of cfDNA were established. Further, the optimum input amount of 
cfDNA for analysis of tissue origins is investigated. Finally, the absolute 
measurement of the tissue origins of cfDNA was shown for six cell types. 
• Chapter 4 aimed to investigate the effect of tissue injury to the tissue 
origins of cfDNA in tissue-specific reporter mice. Paracetamol-induced 
liver injury was performed in mice to confirm expected increase in total 
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cfDNA and contribution of liver to cfDNA. Further, comparison of cfDNA 
analysis and existing protein biomarker was performed to show the 
utility of cfDNA analysis as a biomarker of paracetamol-induced liver 
injury in clinical samples. 
• Chapter 5 aimed to screen for potential candidates of biomarkers for 
detection of CRC using WGS of a mutant rat model. Various types of 
tumour-specific alterations, including single nucleotide variants, short 
indels, structural and copy number variants, as well as LOH variants 
were screened in CRC of the Pirc rat. Additionally, screened LOH 
variants were validated using ddPCR assays. 
 
 




Chapter 2 Materials and Methods 
 
2.1 Rodent Samples 
2.1.1 Mouse breeding 
 
Mouse breeding was carried out in individually ventilated cages (4-6 mice per 
cage depending on litter size) with constant access to food and water in the 
Biomedical Research Facility (BRF), University of Edinburgh (UoE) under 
Home Office project license PPL P1070AFA9. Myeloid (LysM Cre) [73], 
lymphoid (hCD2-iCre) [74], cardiomyocyte (cTnT Cre) [75], hepatocyte (Alb 
Cre) [76] and striated muscle (MCK Cre) [77] Cre mice were obtained from the 
Jackson laboratory (Bar Harbor, Maine) in C57BL/6 background. Erythroid 
(EpoR Cre) [78] mice were obtained from Prof. Stuart Orkin (Cooperative 
Centers of Excellence in Hematology, Bostons Children’s Hospital). These Cre 
mice were bred with mice carrying floxed mT/mG dual reporter gene (Figure 
2.1.1.1) [79] was generated in C57BL/6 background to obtain cell/tissue-
specific reporter F1 mice. Genotyping of F1 litter was performed by Transnetyx 
(Cordova, Tennessee, USA) on ear notch samples to confirm the presence of 
Cre recombinase and the floxed mT/mG gene. Male tissue-specific reporter 
mice (F1, n > 10 for each mouse line), that were heterozygous for Cre 
recombinase and the floxed mT/mG gene, were culled at 10-12 weeks old via 
exposure to gradually increasing concentrations of carbon dioxide gas 
(schedule 1 method) at 10% displacement rate (chamber volume / minute). 





Figure 2.1.1.1 A schematic diagram of the mT/mG reporter gene before and after 
recombination. 
The mT/mG reporter gene is driven by chicken beta-actin core promoter (pCA). Prior to Cre 
recombination (top), the mT/mG reporter gene contains a membrane-targeted mTomato (mT) 
flanked by two loxP sites (shown by black tiangles) and a membrane-targeted enhanced green 
fluorencent protein (mG). Both mT and mG are followed by a polyadenylation sequence (pA). 
Following Cre recombination (bottom), mT and its polyadenylation sequence are removed, 
leaving a loxP site and mG. The illustration is taken from [79]. 
 
2.1.2 Induction of APAP overdose in mice 
 
Induction of paracetamol (APAP) overdose in mice were carried out under the 
Home Office project license PPL 70/7847 (Prof. Stuart Forbes, UoE). To 
induce APAP overdose in mice, mice were injected intraperitoneally (IP) with 
APAP at 350 mg/kg mouse body weight, then maintained at 30°C while given 
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semi-solid food for a certain period of time, and finally culled via exposure to 
increasing carbon dioxide (schedule 1 method) as previously described in 
Section 2.1.1.  
To investigate the timepoint where cfDNA concentration is highest following 
APAP overdose, culling and plasma collection were performed at 8, 24 and 48 
hours following APAP injection in C57BL/6 mice (n = 4 per time point). 
Negative control mice injected with saline were included in each experiment. 
Following investigation in C57BL/6 mice, APAP overdose was induced in 
hepatocyte-specific gene reporter mice (n = 4). Culling and plasma collection 
for hepatocyte-specific reporter mice were performed at 8 hours following 
APAP dosing. 
 
2.1.3 Rat Samples 
 
Rat samples, including frozen and paraffin-embedded colonic tissues, were 
obtained from Dr. James Amos-Landgraff (University of Missouri, USA). Rats 
in this study were all female, inbred, aged between 77 to 276 days on August 
Copenhagen Irish (ACI) background strain (Table 2.1.3.1). The genotypes of 










Table 2.1.3.1 Genotype and age of rats used in the study 
Animal Number Strain Genotype of Apc (Pirc or WT) Sex Age (Days) 
7 ACI WT F 247 
8 ACI Pirc/+ F 247 
9 ACI Pirc/+ F 247 
10 ACI Pirc/+ F 276 
12 ACI WT F 276 
13 ACI Pirc/+ F 77 
36 ACI Pirc/+ F 77 
37 ACI Pirc/+ F 77 
38 ACI Pirc/+ F 77 
39 ACI Pirc/+ F 77 
317 ACI Pirc/+ F 188 
390 ACI Pirc/+ F 184 
391 ACI Pirc/+ F 184 
393 ACI Pirc/+ F 184 
521 ACI Pirc/+ F 156 
526 ACI Pirc/+ F 156 
935 ACI Pirc/+ F 220 
943 ACI Pirc/+ F 219 
944 ACI Pirc/+ F 219 
945 ACI Pirc/+ F 219 
946 ACI Pirc/+ F 219 
1006 ACI Pirc/+ F 161 
1014 ACI Pirc/+ F 161 
 
2.2 Human Samples 
 
Serum was collected from healthy volunteers (n = 11) and APAP overdose 
patients (n = 8) from the SNAP Clinical Trial [80] by Dr. James Dear (UoE). 
The overdose group was comprised of two groups: normal alanine 
aminotransferase (ALT, n = 4) and raised ALT (n = 4), indicating 
clinical/biochemically apparent liver injury. The protocol was approved by the 
Scotland A Research Ethics Committee, UK (ref no 10/MRE00/20). 
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2.3 Sample pre-processing 
2.3.1 Collection and processing of tissue samples 
 
Tissue samples were collected from mice post-mortem and stored at -70°C 
prior to analysis. Some tissue samples were incubated overnight in 40ml of 
formalin, and ethanol 70% until they were processed to be paraffin-embedded 
in the Pathology department, UoE. Paraffin-embedded tissues are stored at 
room temperature prior to analysis. 
 
2.3.2 Collection and processing of blood samples 
 
Blood samples were collected from mice post-mortem via the inferior vena 
cava using 1ml syringes with a 25G needle into EDTA tubes, and then mixed 
by inverting tubes for 3-5 times. Plasma was obtained by centrifugation of 
blood at 1000g for 10 minutes, then 16000g for 5 minutes, within 3 hours of 
blood collection. Mouse blood samples were processed at room temperature. 
Plasma samples were stored in -70°C prior to analysis. 
Blood from clinical samples were centrifuged at 1000g for 15 minutes at 4°C 
and the supernatant was separated into aliquots and stored at -70°C prior to 
analysis. The protocol was approved by the Scotland A Research Ethics 
Committee, UK (ref no 10/MRE00/20).  
 
2.3.3 gDNA extraction 
 
gDNA was extracted from frozen tissue samples using DNEasy blood and 
tissue kit (QIAGEN) according to manufacturer’s instruction. gDNA was stored 




2.3.4 Cell-free DNA extraction 
 
cfDNA was extracted from plasma or serum samples using the QIAamp 
circulating nucleic acid kit (QIAGEN) according to the manufacturer’s 
instructions. cfDNA samples were stored in -20°C prior to analysis. cfDNA 
samples were eluted from column using 50µl of elution buffer. 
 
2.3.5 Bisulphite conversion of DNA and cfDNA 
 
Bisulphite conversion of DNA and cfDNA was performed with the Epitect DNA 
bisulphite conversion kit (QIAGEN) using protocol for low input fragmented 
DNA. Bisulphite converted DNA was eluted from the QIAGEN column using 
50µl of elution buffer. 
 
2.3.6 Quantitation of DNA 
 
gDNA samples extracted from tissues were quantified using Qubit dsDNA 
Broad Range assay (ThermoFisher Scientific) according to the manufacturer’s 
instruction. Bisulphite converted DNA was quantified using Qubit ssDNA assay.  
 
2.4 Histological analysis of tissue samples 
2.4.1 Histological analysis of paraffin embedded tissue 
samples 
 
Sections of 5µm were cut from paraffin-embedded tissues using a microtome. 
These sections were put on a slide and stained with hematoxylin and eosin 
(H&E). Sectioning and staining were performed by Dr. Helen Caldwell in the 
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Pathology Department, UoE. Slides were visualised using NDP Nanozoomer 
slidescanner. 
 
2.4.2 Histological analysis of frozen tissue samples 
 
Fluorescence microscopy of frozen tissue sections from reporter mice was 
performed to visually confirm Cre recombination in tissues, based on 
expression of cell membrane-localised enhanced green fluorescent protein 
(mG) and cell membrane-localised tdTomato (mT). Sections of 5µm were 
obtained from frozen tissues using a cryostat at 4°C. These sections were put 
on a slide with mounting medium prolong gold and DAPI to stain nuclear DNA 
and left overnight at 4°C. Sectioning and staining were performed by Dr. Helen 
Caldwell in the Pathology Department, UoE. Slides were visualised using a 
Britemac epifluorescence microscope in the Institute of Genetics and 
Molecular Medicine (IGMM) Advanced Imaging facility, UoE, with non-




2.5 Polymerase chain reaction 
2.5.1 Quantitative polymerase chain reaction (qPCR) 
 
qPCR assays were performed on the beta-actin (ACTB / Actb) gene [45, 81] 
with SYBR Green to measure total concentration of cfDNA from mice and 
clinical samples. A standard curve of human or mouse gDNA was used in 
quantification. The standard curve was generated through serial dilution and 




2.5.2 Droplet digital polymerase chain reaction 
2.5.2.1 ddPCR for measurement of tissue origins of cfDNA 
 
A probe-based ddPCR assay was designed to specifically quantify the number 
of 1lox and 2lox mT/mG alleles. The assay was adapted from a probe-based 
qPCR assay [82] and designed using Primer3 [83] following the Biorad ddPCR 
application guide, with a maximum amplicon size of 130bp to accommodate 
for small fragments of cfDNA. The assay was validated by amplification of 
gDNA containing only 1lox or 2lox DNA fragments by ddPCR (Table 2.5.2.1.1). 
  
Table 2.5.1.1.1 Oligonucleotides for amplification of 1lox and 2lox mT/mG gene. 





1lox assay consisted of mTmGF1, mTmGR and mTmGP. 2lox assay consisted of mTmGF2, 
mTmGR, mTmGP. FAM: 6-carboxyfluorescein; BHQ: black hole quencher. 
 
An input of 10ng of cfDNA was required for each well of ddPCR. Amplification 
of 1lox and 2lox alleles were performed in separate wells. Each sample was 
measured at least in triplicate. The amplification was run on a thermal cycler 
as follows: 10 min of activation at 95°C, 40 cycles of a two-step amplification 
protocol (30s at 94°C denaturation and 60s at 60°C), and a 10-min inactivation 
step at 98°C. 
 
2.5.2.2 ddPCR for measurement of liver contribution in human cfDNA 
 
ddPCR was performed to measure the contribution of liver tissue to cfDNA in 
clinical samples using a methylation-specific ddPCR assay [84] on 10ng of 
bisulphite-converted cfDNA. The assay consisted of a mixture of primer pairs 
and probes (Table 2.5.2.2.1) that specifically amplified a methylated (from liver) 
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and unmethylated (from other tissues) region in the PTK2B gene (chr8: 
27,183,116-27,183,176, hg19). The amplification reaction was run on a 
thermocycler as follows: 10 min of activation at 95°C, 45 cycles of a two-step 
amplification (94°C for 15s and 60°C for 60s), and a 10-min inactivation step 
at 98°C. 
Table 2.5.2.2.1 Oligonucleotides used in liver-specific methylation assay. 











2.5.2.3 ddPCR for detection of LOH in rat samples 
 
Probe-based ddPCR assays were designed across rat chromosome 18 to 
validate the presence or absence of LOH. Dual-labeled probes (FAM and HEX) 
were used for each assay. FAM probes specifically bind to different allele of a 
heterozygous variant compared to HEX probes. ddPCR assays were designed 
using Primer3 [83] following the Biorad ddPCR application guide, with 
maximum amplicon size 130bp. The amplification was run on a thermal cycler 
as follows: 10 min of activation at 95°C, 40 cycles of a two-step amplification 
protocol (30s at 94°C denaturation and 60s at a specific annealing/extension 
temperature on Table 2.5.2.3.1), and a 10-min inactivation step at 98°C. 
 
 
Table 2.5.2.3.1 Oligonucleotide sequences of ddPCR assays for screening of LOH. 
Genomic 
Coordinate Primer F Primer R Probe [FAM/HEX] 
Annealing 
temperature (°C) 
chr18:27100213 GTCAGGAAGACGACTATG GCTGTTCTTCCTCAGA TGAC[A/T]AGCCTACCAACTACAGTGAACGTT 58.1 
chr18:27043184 CAGTCCAGACTGTTGCTAGA GGCTCTGGGTTTTCTTTACAA CAGCAACA[C/T]ATAAAAGAATACCCAAACA 52.7 
chr18:27112121 GAGAGACACATCGCATACAT GGGTTTTGCTGACAAAT ACATTATGTCTATG[C/T]ATATATGACAAATT 52.7 
chr18:28062387 ACTGTGAGCCCTTTTTCTCC CCACCTCAGCACAGGTAATC TG[G/T]AATGCCTTTGTGTTTCCACTT 62 
chr18:25461411 CCTGAGATCTACTTGCTC GCCATCAGTGGATGACTA TGGACACAA[A/T]AGAGCTCTCTGAAGGAACG 62 




2.6 Fragment analysis of cfDNA 
 
Fragment analysis of cfDNA was performed using Agilent DNA Bioanalyser 
high sensitivity chip at the Welcome Trust Clinical Research Facility. 
 
2.7 Analysis of protein biomarkers from plasma and 
serum samples 
 
Liver function tests (alanine aminotransferase / ALT, aspartate 
aminotransferase / AST, albumin (ALB), bilirubin, and glutamate 
dehydrogenase / GLDH) were measured from mouse plasma and human 
serum samples by Dr. Forbes Howie at the Shared University Research 
Facility, UoE. 
 
2.8 Absolute measurement of the tissue origins of 
cfDNA 
 
Absolute measurement of the tissue origins of cfDNA in mice was achieved by 
analysing cfDNA from F1 tissue-specific reporter mice. cfDNA originating from 
the cells of interest, which express Cre recombinase from a cell-specific 
promoter, were recombined (1lox), as opposed to unrecombined (2lox) from 
other cell types in the body that do not express Cre recombinase (Figure 2.8.1). 
Analysis of Cre recombination in gDNA and cfDNA of tissue-specific reporter 
mice was performed to show successful recombination in mouse tissue and 
the contribution of the corresponding Cre-driven cell/tissue types to cfDNA. 
The metric used to show Cre recombination was percentage recombination 
(1lox%). 




Figure 2.8.1 A schematic representation of the overall strategy for absolute quantitation 
of the tissue origins of cfDNA. 
A conditional deletion is generated in the tissue of interest (e.g. liver) for each mouse model, 
containing a tissue/cell-specific Cre recombinase and the reporter gene floxed mT/mG. Cre 
recombination occurs in target cells/tissues, causing deletion of a loxP site and the mT gene, 
leaving one loxP site in the DNA (1lox), and enabling the expression of the mG gene (green-
colored) as opposed to other tissues in the body that contain two loxP sites (2lox, colored red). 
Histology and DNA analysis are performed in mouse tissues to confirm Cre recombination. 
cfDNA, containing a mixture of 1lox and 2lox alleles released by various tissues through 
normal tissue turnover, can be extracted and analysed to reveal absolute contribution of cell-
type/tissue of interest.  
 
2.9 Whole genome sequence analysis 
2.9.1 Whole genome sequence generation and mapping to 
reference genome 
 
gDNA extracted from normal liver tissue of a ACI wildtype rat (Apc+/+), and 
paired liver-colonic tumour tissue of two ACI-Pirc rats (ApcPirc/+). DNA samples 
were sent to Edinburgh Genomics for library preparation with the Illumina 
TruSeq Nano kit followed by sequencing on the Illumina HiSeqX platform at 
30x and 60x average coverage for liver and colonic tumour DNA respectively. 
The raw sequence data was delivered in fastq file format and analysed 
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alongside an F344N/Crl rat genome publicly available [85]. The fastq files were 
mapped to Brown Norway rat (Rattus norvegicus) reference genome from the 
UCSC genome browser (RGSC Rnor_6.0) [86, 87]. Pre-processing of 
sequence data to obtain analysis-ready alignment files (.bam) was performed 
according to the best practices from the Genome Analysis Toolkit (GATK) [56]. 
 
2.9.2 Detection and validation of somatic LOH 
 
Analysis ready alignment files were processed with HaplotypeCaller to obtain 
a file containing germline variants (.vcf) according to the best practices from 
GATK [56]. To screen for somatic LOH, variant files were filtered based on 
genotyping quality (GQ) above 30, and per sample depth above 20. The 
analysis was also restricted to biallelic variants that passed GATK default hard-
filtering criteria. Chromosome, genomic coordinate, and allele depth for each 
sample was extracted from the filtered variant file using bcftools. Alternate 
allele balance for every sample was calculated from the allele depth data. 
Alternate allele balance values were plotted for each paired liver-colonic 
tumour sample per chromosome to screen for deviation in alternate allele 
balance of the tumour sample from the germline liver sample. 
To approximate the beginning and ending of LOH, circular binary 
segmentation analysis [88] was performed using an R package, called PSCBS 
[88], on a metric describing the allelic shift between the normal and tumour 
sample, called the pseudo odds: 
pseudo odds = (012)&) (0#2)&
⁄ )
(!12)&) (!#2)&)⁄ , 
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nrd referred to the depth of reference allele in a normal sample, nad referred 
to the depth of alternate allele in a normal sample, trd referred to the depth of 
reference allele in a tumour sample, and tad referred to the depth of alternate 
allele in tumour sample. 
 
2.9.3 Detection of somatic single nucleotide variants (sSNVs) 
and small insertion and deletion (indel) variants 
 
Somatic single nucleotide variants (sSNVs) and small indel variants were 
detected by using three different somatic variant callers, namely Mutect2 [57], 
Varscan2 [89], and Strelka2 [90]. A confident list of sSNVs and small indels for 
each sample were obtained by overlapping sSNVs and small indels from these 
three tools. The confident list contained variants detected by at least two out 
of three somatic variant callers. Variants in the confident list were annotated 
by using snpEff [91] and then compared to the cancer gene census project 
from the COSMIC database for human cancers [92, 93]. 
 
2.9.4 Detection of structural and copy number variants 
 
Structural and copy number variants, including deletions, duplications, and 
inversions, were detected by using two somatic structural variant callers, 
namely Lumpy [94] and Manta [95]. A confident list of structural variants was 
obtained by overlapping variants obtained from both tools and further filtered 
based on allele balance (greater than 0.15 for tumour sample, less than 0.1 
for normal sample) and number of paired-end reads supporting evidence 
(more than 10 supporting evidence). Variants were annotated by using 
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ANNOVAR [96]. A list of genes from exonic variants were compared to the 





Normality of data distribution was analysed using Shapiro-Wilk test.  
Comparison between two independent group was performed using Mann-
Whitney U test. Comparison between 3 or more groups were performed using 
Kruskall-Wallis test. Associations between datasets were analysed using 
Spearman rank correlation test. A more detailed statistical analysis is available 
in Appendix C.  
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Chapter 3 Absolute measurement of the 
tissue origins of cell-free DNA using healthy 




Studies of the tissue origins of cfDNA showed that cfDNA predominantly 
originates from hematopoietic tissues [14, 23–25], with minor contributions 
from liver and endothelial cells [26]. These studies were performed in human 
mainly by comparing DNA methylation patterns or nucleosomal profiling of 
different tissues in cfDNA. Analysis of the tissue origins of cfDNA using 
methylation pattern relies on distinct DNA methylation signatures found in 
different cell types and tissues. These distinct methylation patterns can be 
observed in cfDNA by targeted or whole-genome bisulphite sequencing. 
Targeted bisulphite sequencing of cfDNA using a specific methylation marker 
may reveal the contribution of a specific tissue [24, 84], whereas whole-
genome bisulphite sequencing may reveal the contribution of many tissues of 
known methylation signature [25, 26]. The contribution of liver and white blood 
cells to cfDNA was first discovered using whole-genome bisulphite sequencing 
approach, whereas erythroid cells using targeted bisulphite sequencing 
approach [24, 25]. 
Analysis of the tissue origins of cfDNA using nucleosomal profiling exploits the 
variation of nucleosome positionings between cell types. The boundaries of 
cfDNA fragments correlate with cell type-specific nucleosome positioning, and 
the fragmentation of cfDNA contains evidence of the epigenetic landscape of 
the cells of origin. The tissue origins of cfDNA can be estimated by deep 
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sequencing of cfDNA and comparison of its nucleosomal profile with existing 
nucleosome profiles of human cells. Similar to findings from analysis of DNA 
methylation pattern in cfDNA, analysis of nucleosomal profiling in cfDNA 
showed that blood cells, specifically myeloid and lymphoid, are the major 
contributors to cfDNA [14]. 
There is a substantial discordance between estimates of tissue contribution 
generated by different analytical methods in human. Contributions of tissues 
generated by these studies were presented as relative measures as opposed 
to absolute [1]. Further, comparisons of tissue origins of cfDNA with DNA 
methylation patterns or nucleosomal profiling require several steps to be 
performed, such as DNA bisulphite conversion and sequencing library 
preparation, prior to the actual measurement of tissue origins. This multi-step 
approach may contribute to the variation of estimates between these studies. 
Study of tissue origins of cfDNA in animal models has never been performed. 
Measurements of tissue origins of cfDNA in animal models can provide an 
absolute measurement due to the possibility of generating specific genetic 
alterations in tissue of interest using Cre-loxP recombination system [97]. 
Further, control of different factors, that may contribute to experimental 
variability, such as diet and age, is easier in animal models than in human. The 
subsequent sections of Chapter 3 describe the utilisation of tissue-specific 
reporter mouse models to measure the tissue origins of cfDNA, from 
generation of mouse lines, establishment of measurement assays, and 




3.2 Generation of conditional deletion in tissue-of-
interest 
 
In this project, a specific deletion in tissues of interest was generated using 
Cre-loxP recombination system in mice [97]. Mice homozygous for the floxed 
mT/mG gene (see section 2.1.1) were crossed with mice carrying Cre 
recombinases in tissues of interest. Recombination were expected to occur 
only in the mT/mG gene, and not in other loci in the genome. Mice born from 
this cross (F1) were genotyped to confirm heterozygous genotype for both the 
mT/mG gene and a specific Cre-recombinase. Across six tissue-specific 
reporter mouse lines generated, a minimum of 10 mice were successfully 
obtained for each line. A comparison of mouse body weight at 10-12 week old 
between reporter mouse lines (Figure 3.2.1) showed that hepatocyte-specific 
reporter mice (AlbCre+/-; mT/mG+/-) are significantly heavier than control mice 
without Cre recombinase (mT/mG+/-). The median of body weights from other 
mouse lines are not significantly different from control. Despite showing 
statistically significant difference in body weight, median difference between 
hepatocyte-specific reporter mice and no Cre controls was only 3.3gram. 
Tissue-specific reporter mice showed no adverse phenotype, consistent with 
the previously reported phenotype and with the absence of change in coding 




Figure 3.2.1 Comparison of body weight from different tissue-specific reporter mouse 
lines at 10-12 week old. 
Statistical analysis was carried out using Mann-Whitney U tests separated mouse lines into 
three groups shown by letters above the boxplot (a, b or c). The median body weight of mice 
from the Alb Cre line was significantly different to no Cre controls. 
 
3.3 Design and validation of assay to detect 
conditional deletion in genomic and cell-free DNA 
 
A ddPCR assay was designed and validated to quantify recombination in the 
floxed mT/mG gene. The assay consisted of a combination of primer pairs and 
probe that specifically amplify the 1lox or 2lox alleles of the mT/mG gene. 
Amplification of gDNA was performed to demonstrate specificity for each target 
allele (Figure 3.3.1a and b). Amplification of 2 lox gDNA with the 1lox assay 
showed no positive droplet (Figure 3.3.1a). Amplification of the 1lox gDNA 
with the 2lox assay showed 13 positive droplets out of a total of 16467 (less 
than 0.1%) (Figure 3.3.1b). Assay sensitivity was tested using a dilution series 
of target alleles to show that the assay reproducibly quantifies less than 30 
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target alleles (Figure 3.3.1c). Non-specific amplification was not observed in 






Figure 3.3.1 Validation of ddPCR assays on gDNA containing 1lox or 2lox alleles. 
(a) 1lox ddPCR assay specifically amplified gDNA containing 1lox alleles, (b) 2lox ddPCR 
assay amplified gDNA containing 2lox alleles with less than 0.1% of positive droplets from 1lox 
gDNA. The pink line shows the threshold between positive and negative droplets at 
fluorescence amplitude 3000. (c) Dilution experiment showed both assays robustly detected 
less than 30 targets. Each dot showed mean of 1lox or 2lox copies measured by ddPCR 




3.4 Determination of DNA input requirement and 
minimum number of mice to analyse conditional 
deletion 
 
Aside from assay sensitivity and limit of detection explained in section 3.3, the 
requirement of DNA input into ddPCR assay was determined based on the 
amount of cfDNA that can be extracted from individual mice, and a theoretical 
Poisson probability distribution of the corresponding input amount in ddPCR 
platform (Figure 3.4.1). An input of 10ng into ddPCR allowed for triplicate 
measurement of cfDNA with 1lox/2lox ddPCR assay and high theoretical 
measurement sensitivity. 
An experiment in C57BL/6 mice showed that less than 5ng of cfDNA can be 
extracted from a mouse, and less than 10ng from a pool of 5 mice. More than 
70ng of cfDNA can be obtained from a pool of 10 mice (Figure 3.4.1a). This 
indicated less efficient recovery of cfDNA during extraction protocol using a 
lower volume of plasma.  
The incorporation of DNA template into 20000 droplets during ddPCR occurs 
randomly. However, statistics shows that this random incorporation follows the 
Poisson distribution statistics. A theoretical Poisson probability distribution of 
10ng input DNA (approximately 3333 targets) showed that majority of positive 
droplets had one target molecule per droplet (Figure 3.4.1b). This strategy in 
ddPCR, whereby a certain amount of DNA input is used to ensure that a 







Figure 3.4.1 Determination of ddPCR DNA input requirement. 
DNA input requirement depends on amount of cfDNA that can be extracted from mice and 
optimum Poisson probability distribution in ddPCR platform to achieve limiting dilution. (a) 
Total amount of cfDNA that can be extracted from one, five and ten pooled C57BL/6 mice. (b) 
A Poisson probability distribution of 10ng input DNA into ddPCR platform (approximately 3333 
input target molecule). 
 
3.5 Analysis of conditional deletion in gDNA from 
mouse tissues 
 
Cre recombination was confirmed in expected tissues using ddPCR (Figure 
3.5.1) and fluorescence microscopy (Figure 3.5.2) based on the expression of 
the mT/mG reporter gene prior to analysis of cfDNA. To check for specificity 
of Cre recombination, amplification of gDNA extracted from 16 tissue types for 
each mouse line with 1lox/2lox ddPCR assay was performed. Percentage 
recombination of different tissues of reporter mice was calculated from the 
number of 1lox and 2lox alleles in corresponding tissues. Highest specificity 
was found in hepatocyte and cardiomyocyte reporter lines, where 
recombination was observed in liver and heart, respectively, with minimal 
recombination in other tissues (Figure 3.5.3). Specificity of Cre recombination 
was more variable, but generally lower in the other reporter lines. Cre 
recombination can be observed across tissues of myeloid-specific reporter 
mice. This was likely due to the presence of resident macrophages and 
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difficulty of exsanguinating blood completely from analysed tissues. Lymphoid-
specific reporter mice showed the least sensitivity among the six lines 
analysed in the study.   
 
 
Figure 3.5.1 Confirmation of Cre recombination in tissue-specific reporter mouse lines 
using ddPCR. 
1lox and 2lox alleles were measured using ddPCR in tissues where recombination was 
expected vs. not expected for each reporter lines (n > 10 mice for each line). p-value obtained 





Figure 3.5.2 Visualisation of Cre recombination in liver and heart tissue sections of 
hepatocyte and cardiomyocyte-specific reporter mice. 
 (a) liver of a AlbCre;mT/mG mouse, liver of a mT/mG mouse. (b) heart of a cTnTCre;mT/mG 
mouse, heart of a mT/mG mouse. Green colour in the tissues derived from the expression of 





Figure 3.5.3 Specificity of Cre recombination in tissue-specific reporter mouse lines across tissues. 
Measurements of 1lox and 2lox alleles using ddPCR across tissues showed high Cre recombination specificity in hepatocyte and cardiac muscle-specific 





3.6 Analysis of conditional deletion in cell-free DNA of 
healthy mice 
 
To determine the tissue origins of cfDNA, we analysed cfDNA from the six 
tissue-specific reporter lines using ddPCR. Plasma from 10 or more mice for 
each reporter line was pooled prior to cfDNA extraction, to account for the 
small circulating blood volume of individual mice and the low physiological 
concentration of cfDNA. Sufficient DNA was extracted for triplicate 
measurements of the pooled sample from each line by ddPCR (Figure 3.6.1a). 
DNA fragment analysis confirmed the expected cfDNA fragment size profile 
which followed the mono-, di- and tri-nucleosome pattern associated with 
apoptosis, with larger cfDNA fragments most likely due to tissue necrosis and 
lysis (Figure 3.6.1b). 
Contribution of different cell types to cfDNA was quantified by counting the 
number of 1lox and 2lox alleles in the cfDNA of mice for each reporter line and 
subsequently the percentage recombination (1lox%) for each of the lines was 
calculated (Figure 3.6.1c). Absolute measurement of cfDNA showed that 
myeloid, lymphoid and erythroid lineages were the major contributors to the 
levels of cfDNA in healthy mice, contributing 39.7%, 27.8% and 10.7% 
respectively, with a small contribution from hepatocytes (4.2%). Both 
cardiomyocyte and striated muscle cells had undetectable contribution to the 






Figure 3.6.1 The tissue origins of cfDNA in healthy mouse models. 
(a) Total amount of cfDNA obtained from a minimum of 10 mice (pooled) per reporter line 
measured by qPCR of ACTB gene. (b) Representative cfDNA fragment analysis using the 
Agilent DNA bioanalyser high sensitivity assay from hepatocyte-specific reporter mice. 
Fragments of cfDNA followed mono-, di-, and tri- nucleosome fragment sizes, and large cfDNA 
fragment size, shown by black arrows (c) Percentage recombination (1lox%) for each reporter 
mouse line showing contribution of different cell types to total cfDNA. (d) A cumulative 




This chapter demonstrates the utility of tissue-specific reporter mouse models 
as a platform to examine the tissue origins of cfDNA. Here, the first absolute, 
direct measurement of the tissue origins of cfDNA in healthy mice is presented. 
Experiments in mice show that hematopoietic cells, including myeloid, 
lymphoid and erythroid cells, are the major components of cfDNA in the 
healthy state, with a minor contribution from liver and no detectable 
contribution from cardiomyocytes and skeletal muscle cells. These results 
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show concordance with other indirect methods, such as nucleosomal profiling 
and methylation analysis, that have assessed the tissue origins of cfDNA [14, 
24–26], although these studies show considerable variation in the estimates 
of tissue origin, which may in part be due to the indirect or relative 
measurement methods [1]. 
Aside from tissue contributions from hematopoietic, hepatocyte and muscle 
cells, an unknown tissue contribution of 17.6% is unaccounted. A recent 
investigation of the tissue origins of cfDNA in human using tissue-specific DNA 
methylation patterns revealed that vascular endothelial cells contribute 10% to 
cfDNA pool of healthy individuals [26]. The unknown contribution found in this 
study might be a mixture of contributions from vascular endothelial cells, 
technical variability, and possibly minor contributions from other cell types yet 
to be investigated.  
Measurement in this study benefits from the ability to control external variables, 
further reducing sample variability. This is shown by low variability of body 
weight observed between mouse lines. This experimental design may 
therefore be more accurate and less error-prone than indirect relative methods. 
In this project, the mT/mG reporter gene was chosen as the target allele 
deleted in tissues of interest. The mT/mG reporter gene was selected because 
its expression and deletion does not cause any harmful phenotype in mice. 
The mT/mG reporter gene is located in ROSA26 locus in the mouse 
chromosome 6. It is an ubiquitously expressed locus, thus, eliminating 
variability from potential silencing of local chromatin structure between 
different cell types [79] and nucleosomal spacing in cfDNA. Additionally, the 
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utilisation of reporter gene mT/mG is beneficial because it allows for visual 
evaluation of Cre recombination in mouse tissues. Finally, ddPCR assay can 
be designed and validated around loxP sites of the 1lox and 2lox mT/mG 
reporter gene with high specificity and sensitivity. 
In this project, the tissue-specific reporter mice used were heterozygous for 
the floxed mT/mG gene and Cre-recombinase. Despite having enough target 
alleles to be analysed in tissues and cfDNA, investigation of the tissue origins 
of cfDNA using tissue-specific reporter mice with a homozygous floxed mT/mG 
gene would be more advantageous than heterozygous. Mice with a 
homozygous floxed mT/mG gene would have double the number of target 
alleles to be analysed. This in turn would reduce the number of mice utilised 
for each mice (reduction principle of mouse study). In this project, a decision 
was made to utilise tissue-specific reporter mice with heterozygous floxed 
mT/mG gene as opposed to homozygous because of time constraints in 
breeding these homozygous mice. 
In this study, ddPCR was selected as a platform to analyse cfDNA following 
isolation. Measurement of tissue origins of cfDNA using ddPCR can be 
performed directly following cfDNA extraction from plasma, without the need 
to process samples prior to analysis, such as DNA bisulphite conversion for 
comparison of methylation patterns, or library preparation for nucleosomal 
profiling in human. Additionally, with the right input DNA, measurement using 
ddPCR may provide high accuracy and sensitivity. Altogether, the utilisation of 




Despite having the advantage of high accuracy and sensitivity, analysis using 
ddPCR provides only quantitative information in assessing the specificity of 
Cre recombination in mouse tissues. Analysis of Cre recombination in tissues 
may also be complemented by visualisation of reporter genes in tissues using 
epifluorescence microscopy. This may provide spatial information and show 
whether Cre recombination in tissues occur in the respective tissues or in 
blood cells circulating in the tissues. 
Aside from using ddPCR, measurement of floxed mT/mG alleles in tissues and 
in cfDNA may also be performed using sequencing. Measurement of floxed 
mT/mG alleles using sequencing may involve enrichment of target alleles 
using PCR primers or capture using hybridisation probe and library preparation 
for sequencing. 1lox and 2lox mT/mG alleles may be quantified from 
sequencing depths. This method requires more steps to be performed prior to 
quantitation of target alleles and will likely introduces more errors when 
compared to measurement using ddPCR.  
Compared to studies in human, this study is limited in biological replicates. 
This limitation is caused by limited amount of blood that can be obtained from 
a single mouse. A plasma pool of at least 10 mice was necessary to obtain 
sufficient material for ddPCR assay measurement instead of measurement in 
10 individual mice. This number of mice is carefully selected by taking into 
account the amount of cfDNA that can be obtained, as well as the sensitivity 
and specificity of ddPCR assay. A reduction in input cfDNA amount would 
compromise the ability of ddPCR assays in detecting tissues with low 
contribution to cfDNA. In addition, haemolysis and contamination of large 
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cfDNA fragments that arises from lysis of blood cells during sample processing 
may have led to an overestimation of the fraction of cfDNA derived from white 
blood cells, although blood cell lysis were minimal in all samples used in this 
study. Finally, the contribution of cells measured in this study is dependent 
upon the activity and specificity of Cre-recombinase, which varies between 
reporter lines. Due to non-specific Cre recombination in myeloid and lymphoid-
specific reporter lines, the contribution of myeloid and lymphoid cells to cfDNA 
may be overestimated. Further, for each reporter lines, there may be 
contribution from other tissues which recombination status was not analysed, 
such as brain, skin, and gonad. This specificity issue is similar to investigation 
with other methodology such as analysis of tissue-specific methylation pattern, 
which utilises specific methylation markers of the tissue-of-interest against all 
other tissues in the body [24–26, 84]. 
Further experiments may be performed to show the contribution of 
cells/tissues that are yet to be analysed in this study, such as endothelial cells, 
gonads, as well as kidney, or to show reproducibility of tissue contributions 
found in this study. A similar tissue-specific reporter experiment may be 
performed using a different reporter gene as target allele, such as the Fucci2a 
reporter gene [98], or using a different Cre recombinase under a more specific 
promoter. Alternatively, measurement of the tissue origins of cfDNA may be 
possible using tissue-specific knock-in [99] to insert a sequence of DNA to be 
detected in cfDNA, instead of deletion of a reporter gene. Most importantly, a 
follow up experiment to validate findings from healthy reporter mice should be 
performed. An experiment whereby apoptosis or necrosis is induced in tissues 
 
 56 
with low contribution to cfDNA would validate the robustness of tissue-specific 
reporter models in measuring the tissue origins of cfDNA. Apoptosis or 
necrosis of could also be induced by artificially injuring tissues of interest, a 




Chapter 4 The effect of tissue injury on the 




This chapter discusses the effect of tissue injury to the tissue origins of cfDNA 
in tissue-specific reporter mice. This investigation serves as a validation of the 
measurement of tissue origins of cfDNA in tissue-specific reporter mice. 
 
4.1.1 Current understanding of the tissue origins of cell-free 
DNA following tissue injury 
 
cfDNA is predominantly released into circulation through cellular death 
mechanisms, namely apoptosis and necrosis. It is, therefore, logical to assume 
that an increase of cell death from a specific tissue would increase the 
contribution of the respective tissue in circulation. Various experiments in 
human have confirmed that cfDNA fragments originating from damaged 
tissues can be detected in circulation. These experiments include the detection 
of cfDNA fragments from damaged tissues in patients receiving solid organ 
transplantation [100, 101], patients with myocardial infarction [33], patients 
with traumatic brain injury, and  patients with pancreatitis [32]. These studies 
also confirmed the potential of cfDNA analysis as a biomarker of tissue injury 
in various pathological conditions. 
 
4.1.2 APAP overdose and tissue injury 
 
Paracetamol (N-acetyl-para-aminophenol, or APAP) is an analgesic drug that 
is safe when taken at therapeutic doses. APAP overdose is the most common 
cause of acute liver failure in USA and Europe. Toxicity of APAP (Figure 
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4.1.2.1) is caused by the generation of a metabolite, called N-acetyl-p-
benzoquinone imine (NAPQI), in excess [102]. NAPQI is a reactive metabolite 
that reacts with cellular macromolecules and initiate cellular death [103, 104].  
 
Figure 4.1.2.1 APAP metabolism and mechanisms of hepatotoxicity. 
In the liver, APAP is mainly metabolised by UDP-glucoronosyltransferase (UGT) and 
sulfotransferase (SULT) into non-toxic glucuronide (APAP-GLU) and sulfate (APAP-SUL) prior 
to excretion in the urine. A small proportion (around 2%) is excreted as APAP unchanged in 
the urine. Around 5-9% of APAP is metabolised by cytochrome P450 enzymes, mainly CYP 
2E1 into a highly reactive metabolite, called N-acetyl-p-benzoquinone imine (NAPQI). NAPQI 
is quickly metabolised into into a non-toxic metabolite by conjugation with glutathione (GSH), 
catalysed by glutathione-s-transferase (GST). In APAP overdose setting, excessive NAPQI is 
generated, leading to saturation of GST. NAPQI then binds to cellular protein, forming APAP 
protein adducts (APAP-ADs) and leading to hepatic cell death and injury. Illustration taken 
from [104].  
 
Following APAP overdose, an antidote, called acetylcysteine, can prevent liver 
injury when administered within a few hours of overdose. The decision to treat 
APAP overdose patients with acetylcysteine is currently based on the levels of 
serum biomarker ALT and APAP concentration. However, current markers of 
APAP overdose are lacking in sensitivity and specificity when measured soon 
after APAP overdose, such as at initial presentation to hospital [102]. Pre-
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clinical and clinical studies of APAP overdose have identified new potential 
biomarkers that may provide enhance specificity, such as miR-122, or inform 
mechanistic events, such as keratin-18 for necrosis, GLDH for mitochondrial 
dysfunction, acetyl-high mobility group box 1 protein (acetyl-HMGB1) for 
inflammation, as well as macrophage colony stimulating factor 1 (CSF-1) for 
tissue regeneration [103]. The utility of the analysis of cfDNA as a biomarker 
of APAP overdose has not previously been explored. 
Similar to human, APAP overdose in mice may also cause acute liver injury, 
making mice a very suitable experimental animals for studying metabolic 
function and response following APAP overdose. Further, methodology for 
inducing APAP overdose in mice is well studied [105, 106]. With the 
consideration that there is a clinical need for biomarker of APAP overdose and 
practical ease of doing the experiment in mouse models, in this chapter, APAP 
overdose in hepatocyte-specific reporter mice was performed as a validation 
of results in Chapter 3. 
 
4.2 Induction of APAP overdose in C57BL/6 mice 
 
Prior to induction of APAP overdose in hepatocyte-specific reporter mice, a 
preliminary experiment in C57BL/6 mice was performed to investigate the 
timepoint following APAP dosing whereby cfDNA levels in plasma is highest. 
C57BL/6 mice was injected with standard dose APAP (350mg/kg of mouse 
body weight). This dose allows for non-lethal liver injury in C57BL/6 mice. Mice 
were culled and samples were collected at 8, 24 or 48 following APAP dosing. 
Analysis of cfDNA levels showed that the highest increase of cfDNA 
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concentration (~100-fold) was observed in APAP-dosed mice culled at 8 hour 
compared to mice receiving saline injection (Figure 4.2.1a). Analysis of protein 
biomarkers of liver function test ALT and AST showed that liver injury is 
apparent at each timepoint following APAP overdose, with the highest protein 
concentration at 8 hour and lowest at 24 hour (Figure 4.2.1b-c). No changes 
in the levels of liver biomarker ALB and Bilirubin, indicating the expected 
absence of liver injury at this APAP dose (Figure 4.2.1d-e). Histological liver 
sections at each timepoint after APAP dosing (Figure 4.2.1f) confirmed the 
presence of acute zone 3 coagulative necrosis at each timepoint starting at 8 
hour following APAP dosing. The most severe injury was observed at 24 hour 
following APAP dosing. At 48 hour following APAP dosing, liver started 
regenerating. The timepoint 8 hour following APAP dosing was selected to be 




Figure 4.2.1 The effect of APAP on biomarkers at different timepoints in C57BL/6 mice. 
The concentration of cfDNA (a), concentration of ALT (b) and AST (c) peaked at 8 hours following APAP dosing and decreased after 24 and 48 hours. 
The levels of ALB (d) and bilirubin (e) were unaffected by APAP dosing, indicating the absence of overt liver failure. Histological analysis (f) showed that 






4.3 Analysis of Cre recombination in cfDNA of 
hepatocyte-specific reporter mice following APAP 
dosing 
 
Similar to APAP overdose in C57BL/6 mice, analysis of total plasma cfDNA 
demonstrated an increase of ~100-fold in APAP-dosed hepatocyte-specific 
reporter mice compared to mice receiving saline injection (Figure 4.3.1a). 
Analysis of liver biomarkers, and histological analysis of mouse liver tissues 
confirmed the presence of liver injury (Figure 4.3.1b-f). Furthermore, 
quantification of liver-specific cfDNA using 1lox/2lox ddPCR assay at 8 hours 
post APAP dosing in hepatocyte-specific reporter mice shows hepatocyte 
contribution to cfDNA increased to 77.9%, compared to 4.2% in non-treated 




Figure 4.3.1 The tissue origins of cfDNA following APAP overdose in mouse models. 
Barplots of mean concentration of blood biomarkers from APAP-injected hepatocyte-specific reporter mice (n = 4) and saline-treated negative control (n 
= 10, pooled) at 8 hour following APAP dosing: (a) total cfDNA, (b) bilirubin, (c) AST, (d) ALT, (e) ALB. Error bars showed standard error. (f) H&E staining 
of liver tissues from an APAP-injected hepatocyte-specific reporter mice vs saline-treated negative control showing acute zone 3 coagulative necrosis 




4.4 Analysis of cfDNA in APAP overdose patients 
 
A liver-specific methylation ddPCR assay [84] was validated to analyse cfDNA 
of APAP overdose patients. The assay amplified a region of chromosome 8 in 
the human genome where around 60% of methylation density/percentage was 
observed in liver as opposed to other tissues, such as blood cells, bladder, 
oesophagus, heart, lung, pancreas and small intestine (Figure 4.4.1a). 
Validation of this assay was performed on gDNA from liver and white blood 
cells. The probe that binds to methylated CpG sites originating from liver 
showed high specificity to liver (Figure 4.4.1b). The probe that binds to 
unmethylated CpG sites originating from other tissues, showed non-specific 
amplification in liver (96 positive droplets out of 14266, Figure 4.4.1c). 
 
 
Figure 4.4.1 Specificity and validation of liver-specific  methylation ddPCR assay. 
(a) Genomic coordinate of liver-specific methylation marker and its specificity compared to 
blood and other tissues (bladder, oesophagus, heart, lung, pancreas and small intestine). 
Illustration taken from [84]. Validation of liver-specific methylation assay on gDNA from liver 
and white blood cells. (b) Liver-specific probes bind to methylated CpG sites in liver and not 
in white blood cells. (c) Non-liver probes bind to white blood cells, with few non-specific 
amplicons in liver.  
 
To demonstrate potential applicability of these findings to APAP overdose in 
humans, the total amount of cfDNA and protein liver function biomarkers were 
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measured in the serum of healthy volunteers (n = 11) and APAP overdose 
patients (n=8), a subset of which (n = 4) were not exhibiting clinically apparent 
liver injury based on serum ALT levels (Appendix: Table B.1). On average, 
the concentration of cfDNA in the APAP overdose patients increased by ~126-
fold (Figure 4.4.2a). In patients with clinically apparent liver injury (high ALT), 
total cfDNA increased by ~234-fold, whereas patients without clinically 
apparent liver injury (normal ALT) demonstrated mean total cfDNA increase of 
~18-fold compared to healthy volunteers (Figure 4.4.2a). The increase in total 
cfDNA following APAP overdose in patients was consistent with the increase 
in cfDNA following APAP in C57BL/6 and hepatocyte-specific reporter mice, 
indicating the potential of analysis of cfDNA as a clinical biomarker in APAP 
overdose. 
To further assess the utility of cfDNA as a clinical biomarker, serum cfDNA 
concentration was compared with other conventional biomarkers of liver 
function. Total cfDNA was higher in all patients with APAP overdose than in 
healthy volunteers, although two samples, one from an overdose patient with 
normal ALT (cfDNA = 192.87) and one healthy volunteer (cfDNA = 188.17) 
showed similar cfDNA concentrations (Figure 4.4.2b). Total concentration of 
cfDNA also correlated with levels of GLDH, a novel APAP overdose biomarker 
that measures mitochondrial damage (Spearman correlation 0.85, p-value 
<0.01) with the (Figure 4.4.1c).  
Specific analysis of liver contributions to the cfDNA pool, measured by ddPCR, 
showed the percentage of liver-specific cfDNA fragments increased by ~175-
fold in patients with clinically apparent liver injury compared to healthy 
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volunteers, but no increase in liver-specific cfDNA was observed in overdose 
patients without clinically apparent liver injury (normal ALT) (Figure 4.4.2d, e). 
Although GLDH levels were increased in APAP overdose patient with normal 
ALT, analysis of liver-specific cfDNA indicated that the cfDNA did not originate 
from liver tissue (Figure 4.4.2). 
 
Figure 4.4.2 Analyses of cfDNA and other liver biomarkers in clinical samples. 
Comparison of (a) total concentration of cfDNA between healthy volunteers (HV), APAP 
overdose patients with normal ALT (AON) and high ALT (AOH) and (b) comparison of serum 
ALT and total concentrations of cfDNA, (c) comparison of serum GLDH and total 
concentrations of cfDNA, (d) comparison of percentage of liver-specific cfDNA between 
samples, (e) comparison of serum ALT and percentage of liver-specific cfDNA, (f) comparison 
of serum GLDH and percentage of liver-specific cfDNA. Statistical significance for panel (a) 
and (d) were obtained from Mann-Whitney U test and for panel (b), (c), (e), (f) from 




In this chapter, the utility of tissue-specific reporter mice to measure the tissue 
origins of cfDNA in a pathological scenario was successfully demonstrated. 
Following APAP overdose, an increase of both total concentration of cfDNA 
(around 100-fold) and hepatocyte-derived cfDNA fragments (around 20-fold) 
were observed. This showed definitively that tissues with high turnover and 
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more cellular death contributed more than tissue with lower turnover and less 
cellular death. This also indicated that cfDNA is released by cellular death 
mechanisms. 
The utilisation of mouse models in this study enabled control over variables 
that affects the outcome of the experiment compared to study in human, such 
as age, sex, and dosage of APAP. APAP overdose was induced in male 
hepatocyte-specific reporter mice aged 10-12 week old. The induction of tissue 
injury using APAP was selected in this study because mechanisms of 
hepatotoxicity from APAP overdose is well described [104]. The dosage of 
APAP in this study was selected to be non-lethal for C57BL/6J mice. Further, 
only male mice aged 10-12 week old were used to control for known variations 
of response to APAP in male and female mice, with female mice developing 
less liver injury than male mice at the same dosage of APAP [106]. The 
selection of defined sex and age in this experiment also allows for direct 
comparison of tissue contributions from hepatocyte in healthy hepatocyte-
specific reporter mice in Chapter 3. 
Despite successful demonstration of tissue-specific reporter mice as a model 
to measure the tissue origins of cfDNA, this experiment has limitations. 
Measurement of APAP overdose in mice was done using 4 technical replicates 
at a single, non-lethal dose and culling was performed only at one timepoint 
following APAP overdose. Further experiments with more technical replicates 
and a combination of APAP dose at different timepoints may provide more 
information on the effect of different dosages of APAP over time. Using this 
model, the increase of tissue contribution can only be investigated for 
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hepatocytes. Induction of APAP overdose using other tissue-specific reporter 
mice may be beneficial to show toxicity of APAP outside of the liver because 
it is an area of research that is not well studies to date [107]. 
Measurement of the contribution of hepatocytes/liver in hepatocyte-specific 
reporter mice may also be performed using hepatocyte-specific methylation 
biomarker as an alternative to the floxed mT/mG assay. This method would 
require a comparison of many tissues/cell types in mice and a deconvolution 
step to screen for a region with specific CpG dinucleotide methylation status 
when compared to other tissues. Prior to utilisation in cfDNA, a methylation-
specific ddPCR assay would need to be designed and validated on bisulphite-
converted mouse gDNA. Compared to direct measurement of the floxed 
mT/mG alleles, this approach would involve more steps and could introduce 
more errors. However, measurement using this methylation assay may 
validate measurements of the floxed mT/mG alleles. Further, measurement 
using methylation ddPCR assay may be more applicable to human studies that 
uses similar methylation approach. 
The applicability of findings in mice to human studies was also demonstrated. 
Similar to findings in mice, total concentration of cfDNA was increased in 8 
APAP overdose patients. Previous studies have suggested the utility of cfDNA 
as a clinical biomarker of cell death in a range of clinical conditions [32, 108], 
this study was the first demonstration of the clinical utility of total cfDNA as a 
biomarker for APAP overdose in human. Analysis of total concentration of 
cfDNA showed that total concentration of cfDNA robustly distinguished APAP 
overdose patients from healthy volunteers, suggesting that total cfDNA 
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concentration may reflect exposure to APAP. In overdose patients with raised 
ALT, the increase in cfDNA concentration was greater than in those with 
normal ALT, although all overdose patients had a higher cfDNA concentration 
than healthy volunteers. However, whilst there was also a clear increase in the 
proportion of cfDNA that originated from liver in overdose patients with raised 
ALT concentrations, the proportion of liver-specific cfDNA was not increased 
in overdose patients with normal ALT. This contrasts with the observation of 
increased GLDH in all overdose patients, both those with raised and normal 
ALT. 
Previous studies have proposed GLDH as a marker of liver damage in APAP 
overdose [109], but these data suggest that in APAP patients with normal ALT, 
the rise in total cfDNA and GLDH was not liver-derived and may have been 
due to damage of tissues other than the liver. Given that serum GLDH is a 
measure of mitochondrial damage [110] and that GLDH is expressed 
heterogeneously across mammalian tissues [111], the increase in GLDH and 
cfDNA in patients without clinically overt liver injury may reflect release of 
cfDNA from other tissues, for which further pre-clinical and clinical  work is 
indicated to establish the source. To establish the source of cfDNA following 
APAP overdose, analysis in blood-specific and other reporter lines, such as 
kidney, may provide useful information. Similarly, the contribution of different 
tissues in APAP overdose patients may be analysed using various tissue-





Chapter 5 Screening for somatic mutations as 
candidate liquid biopsy biomarkers in the 




Successful implementation of cancer liquid biopsy requires not only a deep 
understanding of the analyte biomolecule, such as cfDNA, but also requires 
promising tumour-specific alterations to be analysed. Unlike previous result 
chapters, in Chapter 5, a genetically altered rat model of colorectal cancer 
(CRC) is screened for potential candidate biomarkers of liquid biopsy. This 
chapter serves as a preliminary work for applying the analysis of cfDNA in the 
Pirc rat. Candidate biomarkers found in this chapter may be used to further 
develop the Pirc rat as an animal model to study and develop non-invasive 
detection methods of colorectal cancer. 
 
5.1.1 Familial adenomatous polyposis 
 
CRC is one of the most common types of cancer in the world. 
Approximately 35% of all CRC cases are associated with a genetic 
predisposition. Familial adenomatous polyposis (FAP) is an inherited form of 
CRC, which constitutes 1% of all CRC cases. FAP patients develop adenomas 
at an unusually young age. One or more of these adenomas become 
malignant with almost 100% penetrance when left untreated [112]. 
The majority of FAP patients have mutations in the adenomatous 
polyposis coli (APC) gene. The APC gene is a tumour suppressor gene that 
plays a central role in the Wnt signalling pathway, specifically in the 
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degradation of b-catenin in the cytoplasm. Mutation in the APC gene can affect 
the suppression b-catenin and lead to constitutive activation of several genes 
and oncogenes that control cellular growth and division. This results in cellular 
overgrowth and formation of adenomas [112]. A proportion of FAP patients 
carry a heterozygous germline mutation in the APC gene. A somatic mutation 
in the APC gene through allelic loss or truncating deletion serves as a “second 
hit” to the gene and presumes to initiate the growth of these tumours [113]. 
Another proportion of FAP patients have no mutation in the APC gene. 
Currently, identification of novel genes associated with FAP is ongoing [112].  
 
5.1.2 The Pirc Rat: a model for familial adenomatous polyposis 
 
The Pirc rat (ApcPirc/+) is a rodent model of FAP. Similar to a majority of 
FAP patients, the Pirc rat has a heterozygous germline mutation at the Apc 
gene, specifically at nucleotide 3409. The mutation changed the nucleotide 
from adenine to thymine, causing a change in amino acid sequence from lysine 
(AAG) to stop signal (TAG) during translation, This mutation causes the rat to 
develop colonic tumours as early as 45 days of age [114]. 
The Pirc rat was generated through the injection of germline mutagen 
N-ethyl-nitrosourea (ENU) on male inbred F344/NTac rats. Progeny of these 
rats were screened for truncating mutation in the Apc gene [114]. The Pirc rats 
used in this project were ACI/NHsd congenic strain. This was achieved by 
crossing of the Pirc rat with F344/NTac background to inbred ACI/NHsd 
background, and backcrossing to inbred ACI/NHsd rats for at least 17 
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generations to remove residual heterozygosity (personal communication with 
Dr. James Amos-Landgraf). 
Colonic tumours in the Pirc rat (ApcPirc/+) develop through two main 
mechanisms: LOH of the short arm of chromosome 18 without changes in copy 
number, and monoallelic expression of mutant Apc allele in tumours that 
maintain heterozygosity [69, 115]. Outside the Apc region, the genomic 
landscape in colonic tumours of the Pirc rat has not previously been described. 
Additionally, characterisation of LOH in the colonic tumour of the Pirc rat at a 
single nucleotide resolution has not been performed. WGS of colonic tumours 
from the Pirc rat may potentially reveal novel genes associated with FAP and 
provide characterisation of LOH at single nucleotide resolution. In this chapter, 
WGS was performed to characterise the genomic landscape of CRC in the 
Pirc rat and screen for candidate biomarkers for liquid biopsy. 
 
5.2 Histological validation of colonic tissue identity 
 
Identity of colonic tissues in this study were validated by histological analysis 
of H&E-stained tissue sections. A total of 46 colonic tumours from 21 rats were 
identified. A representative tissue section of normal colon tissue and colonic 
tumour are shown in Figure 5.2.1. Colonic tumour tissues were distinguished 
from normal colon tissues by the presence of irregularly-shaped intestinal 





Figure 5.2.1 H&E-stained normal colon and colonic tumour tissues from the Pirc rat. 
(a) a section of normal colon tissue, showing three layers of colon: mucosa, sub-mucosa and 
muscularis propria. Intestinal glands formed by epithelial cells are found in the mucosa layer. 
(b) a section of colonic tumour tissue, with irregularly-shaped intestinal gland, a characteristic 
of neoplastic colon tissue. 
 
5.3 Whole genome sequence generation and variant 
calling 
 
WGS of paired liver-colonic tumour DNA samples from 2 rats was performed 
to identify somatic alterations in the colonic tumour of the ACI-Pirc (ApcPirc/+) 
rat. WGS was also performed on liver DNA from ACI-WT (Apc+/+) rat. These 
sequences were analysed alongside F344N/Crl sequence available from a 
public database [85] because the congenic region of the rats was 
heterozygous for ACI and F344N genome. Table 1 shows the summary of the 
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WGS coverage, and the total number of SNVs and small indels relative to the 
Brown Norway genome reference (RGSC Rnor_6.0). Average coverage for 
tumour samples were above 60x, and germline samples were above 30x. 
Across all samples, more than 70% of the genome were covered at the 
expected coverage. Quality of sequences from Illumina HiSeqX is available in 
Appendix A (Figure A.3-5). High quality sequences were obtained with base 
quality score more than 30. 
Comparison of the percentage of heterozygous variants in the germline DNA 
of the Pirc rat with an inbred rat strain F344N/Crl (Table 5.3.1) showed that 
germline Pirc rat DNA had a higher percentage of heterozygous SNVs and 
indel than F344N/Crl. The difference in the heterozygous variant percentages 
was likely due, in part, to the presence of congenic region in the Pirc rat DNA. 
Visualisation of heterozygous SNVs across chromosomes (Figure 5.3.1 – 
Figure 5.3.5) confirmed the presence of a large region with heterozygous 
SNVs in chromosome 18, and patches of heterozygous SNVs across other 
regions of the genome. Even after backcrossing for at least 17 generations, 
the Pirc rats used in this study showed almost 20% of heterozygosity across 
the genome. This rate of heterozygosity is higher than what one would expect 
for inbred lines. This high heterozygosity across the genome may indicate 
breeding errors made during backcrossing or lack of complete inbreeding of 
the parental strains. Fortuitously, this high level of heterozygosity enabled 
screening for LOH to be performed not only in the congenic region (at 
chromosome 18) but also across the genome.
 
  

















Hom Het Hom Het SNV Indels 
12WTLIVER 106.79 39.12 77.7 3381597 698986 1344503 207911 17.13 13.39 
9PIRCLIVER 120.6 44.18 84.6 3347211 782037 1331612 213231 18.94 13.80 
13PIRCLIVER 101.76 37.28 74.8 3313410 779650 1310670 232314 19.05 15.06 
9PIRCADENOCARCINOMA 226.32 82.91 84.7 3614367 845647 1759343 331725 18.96 15.86 
13PIRCADENOCARCINOMA 216.2 79.2 83.2 3621487 844014 1775879 348696 18.90 16.41 
F344N/Crl 73.72 27 72.5 2409365 271273 748454 60915 10.12 7.53 
Sample description: 12WTLIVER was liver DNA from rat no. 12 ACI-WT (Apc+/+). 9PIRCLIVER and 13PIRCLIVER were liver DNA from rat no. 9 and 13 
ACI-Pirc (ApcPirc/+) respectively. 9PIRCADENOCARCINOMA and 13PIRCADENOCARCINOMA were colonic tumour DNA from rat no. 9 and 13 ACI-Pirc 





Figure 5.3.1 Pattern of heterozygosity in the Pirc rat genome from chromosome 1 to 4. 
Each dot in the plot represent a SNV at a genomic position on the x-axis with alternate allele fraction displayed on the y-axis. The bolder dots appear on 
the plot means more SNVs. Homozygous SNVs are close to 0 or 1, heterozygous SNVs are between 0 and 1. Patches of heterozygous regions are 





Figure 5.3.2 Pattern of heterozygosity in the Pirc rat genome from chromosome 5 to 8. 
Each dot in the plot represent a SNV at a genomic position on the x-axis with alternate allele fraction displayed on the y-axis. The bolder dots appear on 
the plot means more SNVs. Homozygous SNVs are close to 0 or 1, heterozygous SNVs are between 0 and 1. Patches of heterozygous regions are 





Figure 5.3.3 Pattern of heterozygosity in the Pirc rat genome from chromosome 9 to 12. 
Each dot in the plot represent a SNV at a genomic position on the x-axis with alternate allele fraction displayed on the y-axis. The bolder dots appear on 
the plot means more SNVs. Homozygous SNVs are close to 0 or 1, heterozygous SNVs are between 0 and 1. Patches of heterozygous regions are 





Figure 5.3.4 Pattern of heterozygosity in the Pirc rat genome from chromosome 13 to 16. 
Each dot in the plot represent a SNV at a genomic position on the x-axis with alternate allele fraction displayed on the y-axis. The bolder dots appear on 
the plot means more SNVs. Homozygous SNVs are close to 0 or 1, heterozygous SNVs are between 0 and 1. Patches of heterozygous regions are 





Figure 5.3.5 Pattern of heterozygosity in the Pirc rat genome from chromosome 17 to 20. 
Each dot in the plot represent a SNV at a genomic position on the x-axis with alternate allele fraction displayed on the y-axis. The bolder dots appear on 
the plot means more SNVs. Homozygous SNVs are close to 0 or 1, heterozygous SNVs are between 0 and 1. Patches of heterozygous regions are 




5.4 Screening, detection and validation of somatic 
LOH variants in the Pirc rat cancer genome 
 
Comparison of allele balance of heterozygous SNVs were performed between 
paired liver and colonic tumour of each Pirc rat to identify regions with (LOH) 
in the cancer genome (Figure 5.4.1 – Figure 5.4.5). Somatic LOH was found 
only around the Apc locus in chromosome 18 on the tumours from both Pirc 
rats  and in no other chromosomal regions of the entire genome sequenced 
(Figure 5.4.1 – Figure 5.4.6). A comparison of sequencing depth at the Apc 
Pirc locus (chr18:27100213) with the average genome coverage for each 
sample showed no substantial changes in sequencing depth (Table 5.4.1), 
indicating that the LOH occurred in the genome without copy number change 




Figure 5.4.1 Screening for somatic LOH in a colonic tumour of the Pirc rat from 
chromosome 1 to 4. 
The X-axis shows the position in chromosome 18, where the somatic LOH was observed. The 
Y-axis shows the alternate allele fraction of different SNVs. The alternate allele fraction of 
SNVs from germline DNA is depicted with black dots, and tumour DNA with red dots. The 





Figure 5.4.2 Screening for somatic LOH in a colonic tumour of the Pirc rat from 
chromosome 5 to 8. 
The X-axis shows the position in the chromosome, where the somatic LOH was observed. 
The Y-axis shows the alternate allele fraction of different SNVs. The alternate allele fraction 
of SNVs from germline DNA is depicted with black dots, and tumour DNA with red dots. The 




Figure 5.4.3 Screening for somatic LOH in a colonic tumour of the Pirc rat from 
chromosome 9 to 12. 
The X-axis shows the position in the chromosome, where the somatic LOH was observed. 
The Y-axis shows the alternate allele fraction of different SNVs. The alternate allele fraction 
of SNVs from germline DNA is depicted with black dots, and tumour DNA with red dots. The 




Figure 5.4.4 Screening for somatic LOH in a colonic tumour of the Pirc rat from 
chromosome 13 to 16. 
The X-axis shows the position in the chromosome, where the somatic LOH was observed. 
The Y-axis shows the alternate allele fraction of different SNVs. The alternate allele fraction 
of SNVs from germline DNA is depicted with black dots, and tumour DNA with red dots. The 




Figure 5.4.5 Screening for somatic LOH in a colonic tumour of the Pirc rat from 
chromosome 17 to 20. 
The X-axis shows the position in chromosome 18, where the somatic LOH was observed. The 
Y-axis shows the alternate allele fraction of different SNVs. The alternate allele fraction of 
SNVs from germline DNA is depicted with black dots, and tumour DNA with red dots. The 
discontinuous SNVs density was due to the absence of heterozygous SNVs the loci. The 







Figure 5.4.6 Somatic LOH in chromosome 18  in two colonic tumours of the Pirc rat. 
The X-axis shows the position in chromosome 18, where the somatic LOH was observed. The 
Y-axis shows the alternate allele fraction of different SNVs. The alternate allele fraction of 
SNVs from germline DNA is depicted with black dots, and tumour DNA with red dots. The 
discontinuous SNVs density was due to the absence of heterozygous SNVs the loci. 
 
Table 5.4.1 Allelic and total sequencing depth at the Pirc locus  
Sample 
Allelic Depth at 







13PIRCADENOCARCINOMA 17 77 94 79.2 Heterozygous variant 
13PIRCLIVER 21 20 41 37.28 Heterozygous variant 
9PIRCADENOCARCINOMA 11 77 88 82.91 Heterozygous variant 
9PIRCLIVER 23 16 39 44.18 Heterozygous variant 
12WTLIVER 30 0 30 39.12 Homozygous variant 
 
Circular binary segmentation analysis was performed using pseudo-odds to 
identify the start and end genomic coordinate of LOH based on the available 




Table 5.4.2 Genomic coordinates of the somatic LOH regions in two Pirc rat colonic 
tumours. 







18 15729175 19941051 2749 
18 19941529 21709559 2449 
18 21709847 28536304 4966 
18 32169550 32664300 576 
13 
18 4295334 18271596 9209 
18 18271848 18471422 322 
18 18471759 18781003 435 
18 18782934 18789866 13 
18 18791651 19559908 1151 
18 19560906 24209914 6542 
18 24210077 29216472 3865 
18 58729422 58789676 121 
 
A ddPCR assay was designed to quantify allele balance of the single 
nucleotide variants in the Pirc locus and was then validated on gDNA extracted 
from the Pirc rat colonic tissues (Figure 5.4.7). A clear separation between 





Figure 5.4.7 Validation of ddPCR assay to measure allele balance in the Pirc locus over 
a temperature gradient. 
The X-axis showed number of droplets for each temperature replicate (event number), which 
was roughly less than 20000 droplets. The Y-axis showed the fluorescence amplitude emitted 
by each droplet. 
 
Somatic LOH in the Pirc locus of two whole-genome sequenced tumours was 
validated using the custom-designed ddPCR assay. This assay was then 
performed on 46 colonic tumour samples from 21 different Pirc rats (Figure 
5.4.8). All 46 tumours showed a shift in allele balance from 0.50 compared to 
their paired-germline DNA, indicating LOH in the Pirc locus of every tumour. 
The allele balance of the SNV in the tumours varied between 0.13 and 0.44. 
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Following successful LOH validation and screening in the Pirc locus of 46 
tumours, 5 more ddPCR assays were designed to screen for LOH across 
chromosome 18. These ddPCR assays cover the beginning and end of the 
Apc gene, 2Mbps upstream and downstream of the Apc Pirc locus, as well as 
close to the long arm of chromosome 18 (Table 5.4.3). Across 46 colonic 
tumours, a majority of tumours (92.68%) have LOH spanning the whole Apc 
gene. The percentage of tumours with LOH dropped to 53.85% 2Mbps 
upstream of the Apc Pirc locus. No LOH was observed at the end of 
chromosome 18. These results suggest that heterozygous variants across the 
Apc gene of colonic tumours of the Pirc rat may be potential candidates of 
biomarkers to be detected in cfDNA of this model. Further, the difference of 
start and endpoint of LOH between tumours of the Pirc rat indicated the 
presence of inter-tumour heterogeneity in this model, despite all of the tumours 
arising from colon tissue. 
 
Table 5.4.3 Screening of LOH across chromosome 18 of the Pirc rat cancer genome 
Genomic 
Coordinate Info 
Percentage of Tumour with 
LOH 
chr18:27100213 Pirc Locus 100.00 
chr18:27043184 Beginning of Apc gene 92.68 
chr18:27112121 End of Apc gene 92.68 
chr18:28062387 28mb with LOH 92.68 
chr18:25461411 25mb 53.85 







5.5 Screening for somatic single nucleotide, small 
insertion and deletion variants in the cancer 
genome of tumours from two Pirc rats 
 
Screening for sSNVs was performed to identify single base substitutions in the 
Pirc rat cancer genome, which can ultimately be detected in cfDNA. Three 
somatic variant callers were used to identify sSNVs from the WGS alignment 
files. A total of 9010 and 9939 sSNVs (Figure 5.5.1) were identified in two 
colonic tumours of Pirc rat 9 and 13 respectively. Among these sSNVs, 469 
and 1051 were found by at least two out of three of the somatic variant callers. 
These high confidence sSNVs were then functionally annotated based on 
putative impacts using snpEff, then compared to cancer gene list from the 
cancer gene consensus project of the COSMIC database to identify any 
sSNVs that had been reported in human cancer. Following functional 
annotation, the majority of the sSNVs had modifier impact, meaning that the 
change occurred at the non-coding region of the gene. Eleven variants (with 
modifier impact) occurred on the same gene from both samples. Of most 
interest were two missense variants found in tumour sample 9, which occurred 






Figure 5.5.1 Somatic single nucleotide variants found by three somatic variant callers 
from whole genome sequence of the tumours of Pirc rats 9 and 13. 
 
 	
Figure 5.5.2 Somatic small insertion and deletion variants found by three somatic 
variant callers from whole genome sequence of the tumours of Pirc rats 9 and 13. 
 
Screening for small insertion and deletion variants was performed to identify 
small insertions or deletions (2-50bp) in the Pirc rat cancer genome, which 
could ultimately be detected in cfDNA. Just like sSNVs, small indels were 
detected by using three somatic variant callers. A total of 4374 and 4827 small 
indels (Figure 5.5.2) were identified in two colonic tumours of Pirc rat 9 and 
13 respectively. Among these small indels, 155 and 311 were found by at least 
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two out of three of the somatic variant callers. These high confidence small 
indels were then functionally annotated based on putative impacts using 
snpEff. Forty-eight small indel variants (with modifier impact) occurred on the 
same gene from both samples. Of most interest was a variant found in tumour 
sample 9, which occurred in Clp1. 
 
5.6 Screening for structural and copy number variants 
in the Pirc rat cancer genome 
 
Screening for structural and copy number variants were performed to identify 
structural deletions, duplications, inversions and other complex structural 
rearrangements that occurred in the Pirc rat cancer genome. A total of 601 and 
581 structural variants were detected for sample 9 and 13 respectively (Table 
5.6.1), a majority of which were intergenic variants. A list of genes that resides 
within genomic coordinates of exonic variants were obtained and compared to 
previously-known cancer genes from COSMIC database for human cancer. Of 
most interests were CCNE1, CEBPA, and MYOD1 genes. These genes were 
found to be duplicated in the tumour samples analysed. Additionally, copy 
number gains and overexpression of these genes were reported in the 










Table 5.6.1 Structural and copy number variants of the Pirc rat cancer genome. 






























































In this chapter, WGS was performed to show somatic mutations in the cancer 
genome of the Pirc rat. Understanding somatic mutations in cancer genome 
may help understand how tumours develop, identify targets for therapy and 
novel biomarkers for detection of cancer. Specific for FAP patients, novel 
information on somatic mutations may help in diagnosing patients without 
genetic diagnosis to date. Further, genomic alterations found in this study 
serves as candidate biomarkers to be tested in cfDNA of the Pirc rat. Whole 
genome analysis of colonic tumours of the Pirc rat showed LOH in a large 
region of chromosome 18, including the Apc gene that may play a central role 
in tumourigenesis in the Pirc rat. Additionally, single nucleotide variants, small 
indels and structural variants were found in cancer genes linked with CRC in 
human. 
Prior to whole genome analysis, the identity of colon tissue samples was 
validated using histological analysis of tissue sections stained with H&E. 
Histological analysis to date is still the golden standard for clinical diagnosis of 
tumours. This involves visual examination of cellular shapes to determine 
whether a tissue is cancerous  [116]. In this project, the presence of irregularly-
shaped intestinal glands confirmed the identity of colonic tumour tissues. This 
ensures the validity of subsequent analysis and helps to avoid false results 
from analysing wrong tissues. 
WGS of tumour tissues in this study was performed at 60x average depth, as 
opposed to 30x in the germline. This deeper depth was selected because 
characterisation of somatic alterations from tumours can be challenging 
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because of variable tumour cellularity, polyploidy, and the presence of clonal 
heterogeneity. Sequencing depth of tumours at 30x is insufficient to detect 
variants with allele fraction of less than 15%, and at 50x of less than 10%. A 
sequencing depth of 200-300x is known to be required in order to facilitate 
variant discovery with less than 10% variant allele fraction [117]. 
WGS was performed on DNA from colonic tumours and matched germline 
DNA from liver in two individual rats (number 9 and 13). A matching germline 
DNA is considered essential for cancer genome sequencing to remove 
germline variants [117]. In this study, germline DNA was selected from liver 
and not adjacent normal colon tissue because adjacent normal colon tissues 
are predisposed to develop as tumours and may genetically have already 
accumulate mutations. 
Sequence files generated in this study were of high quality, with base quality 
phred score above 40 across the sequencing reads. A phred score is a widely 
accepted measure of the probability that the base from sequencing is called 
correctly [118, 119]. Phred score of 40 in this study means that the probability 
of incorrect base call in this study is 1 in 10000 bases, supporting that variants 
in found in this study may be genuine variants and not due to sequencing 
errors. 
Successful screening of LOH using WGS in this study extends LOH that has 
previously been found in the Pirc rat [115] at a single base resolution. 
Screening across different regions of chromosome 18 of the Pirc rat cancer 
genome with ddPCR confirmed that the Apc gene contained heterozygous 
variants that are promising biomarkers that could be detected in cfDNA. 
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Detection of these variants in cfDNA may extend the utility of the Pirc rat, not 
only as a model to study pathology of FAP, but also to study non-invasive 
detection of the disease. Variants of LOH may be potential candidates for non-
invasive detection of cancer. This has previously been shown in patients with 
prostate cancer by the analysis of short tandem repeat sequences [120]. A 
careful design of assay to detect LOH in cfDNA is important, considering 
cfDNA of cancer patients consist of contributions from healthy tissues, such as 
hematopoietic and liver as previously found in Chapter 3, in addition to 
fragments originating from tumour cells. 
During the screening of LOH using ddPCR at the Apc Pirc locus, a variability 
of alternate allele fraction in the tumours was observed, ranging from 0.18 to 
0.44. This variability may be caused by differences in tumour cellularity, the 
fraction of malignant cells to healthy cells in tumour tissues analysed. 
Additionally, this variability may also be contributed from intra-tumour 
heterogeneity, the heterogeneity that arises in tumour cells within each tumour 
tissue. 
Screening of LOH using ddPCR at several different loci of the chromosome 18 
across 46 tumours also highlighted the presence of heterogeneity between 
colonic tumours of the Pirc rat (inter-tumour heterogeneity). LOH was found in 
all 46 colonic tumours at the Apc Pirc locus. The percentage of tumours with 
LOH across the whole Apc gene dropped to 92%. Less than 60% of the 
tumours have LOH at 2Mbps upstream of the Pirc locus. 
The presence of inter-tumour heterozygosity would affect the detection LOH 
using cfDNA. The circulation of a tumour patient contains cfDNA arising from 
 
 100 
normal cellular turnover and ctDNA from tumour tissues [22]. The detection of 
LOH in cfDNA would rely in the detection of relatively small shifts in allelic 
balance from 0.5 (heterozygous). In this case, the utilization of LOH 
biomarkers that are consistent between tumours would be beneficial 
compared to ones that are not. LOH biomarkers that are consistent between 
tumours would give stronger signal when detected in cfDNA compared to the 
inconsistent ones. It is, therefore, suggested to start the investigation of LOH 
biomarker utility in the Pirc rat using an assay designed for the Pirc locus. 
In addition to confirmation of LOH in chromosome 18, analysis of single 
nucleotide variants, small indels, and structural variants were performed. 
Confident variants from these analyses were obtained by using multiple variant 
callers and intersecting the results to reduce false positive. The use of multiple 
variant callers to date is still considered an optimal strategy to improve analysis 
performance [117]. 
Following screening for somatic variants, the confident list of variants obtained 
in this study was compared with a list of variants from cancer gene census 
(COSMIC databse) in human [92, 93]. The list of cancer genes from cancer 
gene census consisted of expert-curated genes that drives human cancer and 
used as standard cancer genetics across basic researches. Tier 1 genes from 
the cancer gene census consisted of genes with documented activities 
relevant to cancer along with evidence of mutations in cancer that change the 
activity of the gene product that promotes tumourigenesis. Tier 2 genes 
consisted of genes with strong indications of roles in cancer with less extensive 
evidence available [92]. In this study, variants were found in genes included in 
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the cancer gene census. These genes are Bcor, Plag1, Clp1, Ccne1, Cebpa, 
and Myod1. Bcor is a tier 1 gene from cancer gene census. Inactivation of Bcor 
have been identified in various haematological cancers [121]. Further, single 
nucleotide variants of Bcor have been observed in colonic adenocarcinoma in 
cancer patients [122]. Overexpression of Plag1 has been observed in various 
tumour types, such as adenoma of salivary glands, hepatoblastoma, 
lipoblastoma and acute myeloid leukaemia [123]. Mutation of the Clp1 gene 
has been observed in human CRC [124] and in mouse model of CRC based 
on mutation in the Apc gene [125]. Copy number alterations of Ccne1 is related 
to poor survival of bladder, breast and ovarian cancer patients [126]. Loss of 
function mutations of Cebpa contributes to the development of acute myeloid 
leukaemia [127]. Myod1 is a putative tumour suppressor gene known to be 
disrupted in breast and CRC [124, 128]. 
Being a preliminary study, this study is mainly limited by the number of 
biological replicates for WGS, due to the limitation of cost. Somatic variants 
may be missed because of the lack of replicates. Additional samples for WGS 
would be required depending on the aim of follow up studies, such as to 
discover novel genes that is involved in tumourigenesis of the Pirc rat. Further, 
time limitation prevented the study of variants found in this project as 
biomarkers to be used in cfDNA. 
Finally, to develop the Pirc rat as a model organism to study non-invasive 
detection of cancer, several steps need to be taken. First, cfDNA from the Pirc 
rat needs to be extracted and quantified. Following cfDNA extraction and 
quantification, an in-silico calculation may be performed to estimate the 
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detection threshold of LOH ddPCR assays and should take into account the 
sensitivity of LOH ddPCR assays. A proof-of-concept experiment can be 
performed to analyse LOH at the Pirc locus on a few cfDNA samples to 
demonstrate the possibility of showing LOH in cfDNA using LOH ddPCR assay. 
Upon successful demonstration, this experiment can then be extended to 




Chapter 6 General Discussion 
 
This PhD project sets out to perform genomic analysis in mouse models to 
investigate the tissue origins of cfDNA and in a rat model to screen for potential 
candidate biomarkers of liquid biopsy to detect CRC. Various findings were 
discovered throughout the study. This includes utilisation of ddPCR assay to 
measure Cre-loxP recombination in tissue-specific reporter mice, the first 
absolute and most direct measurement of the tissue origins of cfDNA in healthy 
mice and in a representative pathological condition of APAP overdose, the 
potential of cfDNA analyses as a biomarker of tissue injury in APAP overdose 
patients, and the first CRC genome sequencing of the Pirc rat. In this chapter, 
these key findings that form the novelty of this PhD thesis, their significance, 
as well as their immediate and longer-term implications in the field of medicine 
were discussed.  
 
6.1 Validation of ddPCR assay to quantify Cre-loxP 
recombination in tissue-specific reporter mice 
 
To perform absolute measurement of the tissue origins of mouse cfDNA, Cre-
loxP recombination in cfDNA of tissue-specific reporter mice was quantified. 
An assay to quantify Cre-loxP recombination in gDNA and cfDNA was 
designed and validated using ddPCR. This assay was adapted from a qPCR 
approach [82]. Successful utilisation of ddPCR to quantify Cre-loxP 
recombination is a substantial improvement from other methods, such as 
southern blotting and qPCR. Quantitation of Cre-loxP recombination in cells 
and tissues is important because it affects the accuracy of an experiment [82]. 
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In this study, for example, quantitation of Cre-recombination in cardiomyocyte-
specific reporter mice showed that there is background recombination coming 
from skeletal muscle cells (less than 5%), but not from other cells (less than 
1%). Compared to qPCR, quantitation of Cre-loxP recombination with ddPCR 
is reference free. This reduces human error, for example during generation of 
standard curve, and allows for more accurate quantitation. Further, the input 
DNA requirement for ddPCR is low, unlike southern blotting that requires more 
than 5ug of DNA [82]. Based on these advantages, it is recommended to utilise 
ddPCR to quantify Cre-loxP recombination when required. 
 
6.2 Absolute measurement of the tissue origins of 
cfDNA in healthy mice 
 
Using tissue-specific reporter mice and a ddPCR assay to quantify Cre-loxP 
recombination, an absolute and most direct measurement the tissue origins of 
cfDNA was carried out. This includes the contribution from six cell types: 
myeloid, lymphoid, erythroid cardiomyocyte and striated muscle cells. Myeloid, 
lymphoid and erythroid cells were major contributors of cfDNA origin in the 
healthy state, contributing up to ~79% of the cfDNA pool in healthy mice aged 
10-12 week old. A minor contribution of ~4% was observed from hepatocytes. 
No contribution was detected from muscle cells. These results complement 
and are concordant with previous findings in human using relative 
measurement method, such as comparison of nucleosomal mapping and 
tissue-specific methylation patterns [14, 24–26]. Around 17% of tissue 
contribution in this study was unknown, and likely to originate from endothelial 
cells, or other cell types that have yet to be investigated. In the short term, 
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these findings are useful for academics and laboratories in designing cfDNA 
assays to detect cancer based on DNA methylation or nucleosomal mappings. 
An understanding of the composition of cfDNA in the healthy state is useful to 
be included in a bioinformatics pipeline for target discovery, aiming to reduce 
false positive results originating from non-target tissues. Aside from cancer, 
this knowledge may also be useful for detection of other pathological 
conditions, where there is any deviation from the rate of cellular turnover in the 
healthy state. In the longer term, these findings may contribute toward 
successful design and implementation of robust, non-invasive assays based 
on cfDNA for various conditions. 
 
6.3 Measurement of the tissue origins of cfDNA 
following tissue injury 
 
Following the absolute measurement of the tissue origins of cfDNA in healthy 
mice, an absolute measurement of the tissue origins of cfDNA was also 
performed in hepatocyte-specific reporter mice following APAP overdose. This 
experiment was the first to demonstrate the utility of tissue-specific reporter 
mice in measuring the tissue origins of cfDNA in a pathological condition. 
Following APAP overdose, an increase of the contribution of hepatocytes from 
~4% to 77% was successfully detected. This demonstration opens up the 
possibility of using tissue-specific reporter mouse models for measurement of 






6.4 cfDNA analysis as a biomarker of tissue injury in 
APAP overdose patients 
 
During the investigation of the tissue origins of cfDNA following APAP 
overdose in mice, it was found that the total concentration cfDNA by more than 
100-fold and contribution of cfDNA from hepatocytes increased by ~20-fold. 
This raised a question whether the analysis of cfDNA can be used as a 
biomarker of tissue injury in APAP overdose patients. To answer this question, 
a preliminary experiment was performed to investigate the ability of both the 
total concentration of cfDNA and liver-derived cfDNA to distinguish APAP 
overdose patients and healthy volunteers. The total concentration of cfDNA 
robustly distinguished APAP overdose patients from healthy volunteers, 
irrespective of an apparent liver injury based on protein liver function tests, 
such as ALT and AST. This indicates that the total concentration of cfDNA may 
be a more sensitive biomarker of tissue injury in APAP overdose patients. 
Unlike the total concentration of cfDNA, liver-derived cfDNA can only 
distinguish patients with apparent liver injury from healthy volunteers, and not 
patients without apparent liver injury from healthy volunteers. This may 
indicate that liver-derived cfDNA reflect a more specific injury in the liver as 
opposed to effects of APAP overdose in other systems in the body. When 
compared with other biomarkers of liver function tests, the total concentration 
of cfDNA is highly concordant with a biomarker of mitochondrial damage, 
GLDH, whereas liver derived cfDNA showed concordant results with ALT. 
Altogether, this preliminary study is the first to show the potential of cfDNA 
analyses in detecting APAP overdose patients. Investigation of alternative 
biomarkers of APAP overdose is important because current APAP overdose 
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markers, such as serum ALT and APAP concentration, lack sensitivity and 
specificity when measured soon after overdose such as at initial presentation 
to hospital [102]. In the short term, these findings may serve as a basis for 
academics and clinicians in designing bigger studies to investigate the utility 
of cfDNA analyses as a biomarker of tissue injury in APAP overdose patients. 
In the long term, this study may contribute toward a novel assay to detect 
APAP overdose in the clinic. 
 
6.5 Genomic landscape of CRC in the Pirc rat 
 
To screen for potential candidate biomarkers for the detection of CRC, WGS 
was performed in two paired colonic tumours and normal colon of the Pirc rat. 
Whole genome sequence analysis showed LOH in chromosome 18 of the Pirc 
rat cancer genome. Validation of LOH across chromosome 18 in 46 colonic 
tumours using ddPCR showed that LOH occurred for all tumour samples in the 
Apc Pirc locus (chr18:27100213) and in the majority (~97%) of the tumours 
across the whole Apc gene. This indicated that LOH in the Apc gene may be 
an important mechanism in tumourigenesis in the Pirc rat and showed that 
SNVs in the Apc gene of colonic tumours of the Pirc rat may be promising 
candidates for detection of CRC. Aside from LOH, various somatic alterations, 
including sSNVs, small indels, and structural as well as copy number variants 
were analysed. Of most interest were notable variants found in both this study 
and previously reported in the COSMIC cancer gene census database [92], 
including sSNVs in Bcor and Plag1, a small indel in Clp1, and structural 
variants in Ccne1, Cebpa and Myod1. These findings, although preliminary, 
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are the first to show the landscape of cancer genome in the Pirc rat. Further, 
this study provides the first characterisation of LOH in the Pirc rat at a single 
base resolution across the genome. These findings formed a basis for follow 
up investigations in the Pirc rat that aims to expand the utility of the Pirc rat to 
as a platform to study liquid biopsy, and as a model to potentially discover 
novel genes for detection of CRC, specifically FAP, in human. Discovery of 
novel genes for FAP is important because a proportion of FAP patients are 
negative for mutations in the APC gene, and do not have a genetic diagnosis 
[112]. In the longer term, these findings may contribute to a novel non-invasive 
assay for detection of CRC in the clinic. 
 
6.6 Follow up studies 
 
Taking into considerations of these key findings, several follow-up 
investigations can be performed. A follow-up absolute measurement of tissue 
origins of cfDNA in the healthy state may be performed using a different 
experimental design, such as utilisation of tissue-specific knock-in mice, 
instead of deletion of a reporter gene, utilisation of Cre recombinase driven by 
other promoters to investigate different cell types, or utilisation of different 
floxed gene. These studies may show the presence or absence of 
contributions from other tissues to expand understanding of the tissue origins 
of cfDNA, and further demonstrate the robustness of mouse models for studies 
of cfDNA. 
A follow up study to investigate the tissue origins of cfDNA may be performed 
using tissue-specific reporter mice in various physiological conditions, such as 
 
 109 
ageing, following exercise and physical stress, or pathological conditions, such 
as following myocardial infarction, alcohol poisoning, or other tissue injuries. 
These studies may serve as an exploration of cfDNA analyses as a biomarker 
for these conditions. Specifically for APAP overdose, a follow-up investigation 
in mice may be beneficial when performed using different doses of 
administration and at earlier as well as later timepoints following APAP 
overdose. This study may show the dynamics of different APAP overdose 
biomarkers, including cfDNA analyses and liver function tests, in response to 
APAP dosage at different timepoint. 
Following preliminary demonstration of cfDNA analyses as a biomarker of 
tissue injury in APAP overdose patients, a follow-up study with more samples 
may be performed to show clinical validity and utility of cfDNA analyses. This 
study may also show the specificity and sensitivity of the total concentration of 
cfDNA and liver-derived cfDNA as a biomarker of APAP overdose. To allow 
for successful implementation of cfDNA analyses as a biomarker of APAP 
overdose in the clinic, establishing a point-of-care assay based on cfDNA may 
be beneficial. This assay would need to have a relatively quick turnaround time 
from sample collection to results interpretation by clinicians, preferably 
comparable to current liver function tests such as ALT and AST. At the moment, 
measurement of cfDNA concentration can be performed in a relatively short 
time using fluorometry, such as Qubit dsDNA assay used in quantitation of 
gDNA in this study. An alternative to Qubit, quantitation of cfDNA using qPCR 
is substantially slower but provides better specificity because it is PCR based. 
 
 110 
An ideal point-of-care tests based on cfDNA would need to have both 
specificity and quick turnaround time. 
Following preliminary analysis of the colonic tumours of the Pirc rat, two 
studies can be performed. First, more colonic tumour samples may be 
sequenced to allow for robust discovery of novel genes to study 
carcinogenesis of FAP. Identification of novel genes in rat model may benefit 
in controlling external variables and in a scenario where paired germline 
genome and sample collection is restricted. The knowledge obtained from 
successful identification of novel genes in FAP may be translated to help 
diagnose APC mutation negative patients [112]. Sequencing additional 
samples may also provide more candidate markers of liquid biopsy to be 
detected in cfDNA to demonstrate the utility of the Pirc rat as a model of CRC 
liquid biopsy.  
Other future work that is not directly related to key findings in this study may 
also be performed. Upon the realisation of low input amount of cfDNA from 
mouse and from healthy individuals, as well as heterogeneity of tumour 
samples and low mutant allele fractions of variants, studies of tumour allele 
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A. Supplementary Figures 
 
Figure A.1 A representative plot of base quality of sequences across sequencing read. 
X axis showed position in read (bp) with maximum of 150bp. Y axis showed average Phred score. An average of more than 30 Phred score was 





Figure A.2 A representative plot of distribution of Phred quality score over all 
sequences. 
X axis showed mean sequence quality (Phred score), Y axis showed the number of sequences. 










Figure A.3 A representative plot of GC content distribution from whole genome 
sequencing. 
X axis showed mean GC content (%), Y axis showed the number of sequences. A bell curved 
distribution of GC content was observed (shown by red line), similar to theoretical GC content 




B. Supplementary Tables 
Table B.1  Measurements of serum biomarkers from APAP overdose patients and healthy volunteers. 
Sample Cohort Biomarkers 




10882.5 22.3 3391 2483 145 40.8 653 95.5 
JD2 255.7 <2.5 5019 1794 280 26.8 504 16.4 
JD3 18998.8 18.7 2251 3049 150 31.7 1056 97.7 
JD4 7351.0 11.9 2795 3114 291 28.9 583 80.7 
JD5 192.9 7.2 11 36 91 38.4 11 0.1 
JD6 1168.9 <2.5 17 26 117 36.4 18 0.3 
JD7 846.4 107 25 85 127 43.4 68 1.2 
JD8 787.5 7.2 17 26 96 39.3 33 0.0 
PS1 
Healthy Volunteers 
188.2 22.6 12 29 117 44.5 11.7 0.0 
PS2 20.5 5.3 14 29 77 37.2 9.1 0.0 
PS3 11.7 4.3 12 52 81 38.7 9.1 1.5 
PS4 49.7 7.8 21 43 <50 41.9 11.7 0.0 
PS5 26.3 12.7 21 27 101.4 43.7 6.5 1.2 
PS6 64.7 2.6 34 32 76 38.8 10 0.5 
PS7 10.5 3.9 16 36 104 40.6 7.8 0.0 
PS8 8.4 6.6 22 35 105 44.3 7.8 0.0 
PS9 21.4 6.5 17 33 126 44.3 13 0.9 
PS10 24.9 9.8 65 26 91 40.3 3.9 0.4 
PS11 13.6 13.0 18 33 135 42.3 3.9 0.0 





C. Statistical analysis 
C.1 Comparison of body weight from different tissue-specific 
reporter mouse lines 
 
A Shapiro-Wilk test was performed to investigate data distribution on 
the animal body weight data set. The null hypothesis of Shapiro-Wilk test is 
the data follow a normal distribution. The alternate hypothesis is the data do 
not follow a normal distribution. Shapiro-Wilk test showed p value of 0.3 (p > 
0.05). Therefore, null hypothesis was not rejected. The data follow normal 
distribution. 
Despite an indication of normal distribution, a non-parametric Kruskall-
Wallis test was selected as opposed to one-way analysis of variance (ANOVA) 
because to perform parametric test ANOVA, the data for each group should 
contain at least 15 data point for 2-9 groups. The null hypothesis Kruskall-
Wallis test is all medians are equal. The alternate hypothesis is at least one 
median is different Analysis with Kruskall-Wallis test showed p value of 9.5 x 
10-7 (p < 0.05). Therefore, null hypothesis was rejected. At least one median 
in the dataset was different. 
A Mann-Whitney U test was selected to find the group with different 
median (Table C.1.1) in the dataset as opposed to student t test due to sample 
size being less than 15 (Table C.1.2). The null hypothesis of Mann-Whitney U 
test is the median between two groups are equal. The alternate hypothesis is 
the median between two groups are not equal. Grouping of tissue-specific 
reporter lines were performed based on p-value from Mann-Whitney U test 
(Table C.1.2). Group A consisted of Alb Cre, EpoR Cre, and MCK Cre. Group 
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B consisted of EpoR Cre, MCK Cre, hCD2-iCre, and no Cre. Group C 
consisted of no Cre, LysM Cre, and cTnT Cre. 
 
Table C.1.1 Median and standard deviation of the body weight of tissue-specific reporter 
mice. 
Mouse line Number of mice 
Animal body weight (g) 
Median Standard deviation 
Alb Cre 13 27.0 2.4 
cTnT Cre 12 23.3 1.7 
EpoR Cre 20 26.2 2.1 
hCD2-iCre 12 25.5 1.4 
LysM Cre 16 23.0 2.0 
MCK Cre 10 25.4 1.2 
no Cre 10 23.7 1.7 
 
Table C.1.2 p-values from comparison of mouse body weight between reporter lines 
with a Mann-Whitney U test. 











Alb Cre NA 0.00 0.44 0.02 0.00 0.05 0.00 
cTnT Cre 0.00 NA 0.00 0.01 0.61 0.01 0.16 
Epor Cre 0.44 0.00 NA 0.06 0.00 0.06 0.00 
hCD2-
iCre 
0.02 0.01 0.06 NA 0.01 1.00 0.17 
LysM Cre 0.00 0.61 0.00 0.01 NA 0.02 0.11 
MCK Cre 0.05 0.01 0.06 1.00 0.02 NA 0.04 
no Cre 0.00 0.16 0.00 0.17 0.11 0.04 NA 
NA: not available. p-values in yellow are less than 0.05. 
 
 
C.2 Confirmation of Cre recombination in mouse tissues 
 
Data distribution of percentage recombination (1lox%) in mouse tissues 
was analysed using Shapiro-Wilk test (Table C.2.1). The null hypothesis of 
Shapiro-Wilk test is the data follow a normal distribution. The alternate 
hypothesis is the data do not follow a normal distribution. Majority of datasets 
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followed normal distribution, except for ear notch of cTnT Cre line, ear notch 
of Alb Cre line, whole blood of LysM Cre line, and ear notch of MCK Cre line. 
Comparison using parametric student t test requires both datasets used in 
comparison to be normally distributed and with at least 15 replicates for each 
dataset. Considering these statistical assumptions, a non-parametric Mann-
Whitney U test was selected to compare tissues within each reporter lines. 
Table C.2.1 Summary of percentage recombination and data distribution based on 
Shapiro-Wilk test in mouse tissues. 
Reporter Line Tissue n 
1lox% 
Shapiro-Wilk p-value 




39.0 3.8 0.65 




28.1 7.1 0.81 




71.6 6.7 0.09 




71.5 5.7 0.90 




14.1 4.8 0.01 




25.9 7.9 0.82 
ear notch 0.2 0.2 0.02 
p-values in yellow are less than 0.05. 
 
Comparison between tissues within each reporter line showed a significant 
difference (Table C.2.2). This confirmed the presence of recombination of the 







Table C.2.2 p-value from a Mann-Whitney U test between tissues with and without 
recombination. 
Reporter line Mann-Whitney U p-value 
cTnT Cre 7.4 x 10-7 
EpoR Cre 6.7 x 10-8 
Alb Cre 1.5 x 10-5 
hCD2-iCre 3.6 x 10-5 
LysM Cre 3.3 x 10-9 
MCK Cre 0.01 
p-values in yellow are less than 0.05. 
 
C.3 Analysis of cfDNA and other liver biomarkers in clinical 
samples 
C.3.1 Comparison of total cfDNA in clinical samples 
 
Data distribution of total cfDNA measured by qPCR of the ACTB gene 
was analysed using a Shapiro-Wilk test. The null hypothesis of Shapiro-Wilk 
test is the data follow a normal distribution. The alternate hypothesis is the 
data do not follow a normal distribution. Shapiro-Wilk test showed p-value of 
5.459 x 10-7 (p-value < 0.05). Therefore, null hypothesis was rejected. The total 
cfDNA data do not follow normal distribution. 
A non-parametric Mann-Whitney U test was used to analysed total 
cfDNA between healthy volunteers (HV), APAP overdose patients with normal 
ALT (AON), and with high ALT (AOH) (Table C.3.1.1). A significant difference 
in median value of total cfDNA was observed between HV and AON, and HV 







Table C.3.1.1 p-value from comparison of total cfDNA between clinical samples. 
p-value HV AON AOH 
HV NA 0.001 0.001 
AON 0.001 NA 0.2 
AOH 0.001 0.2 NA 
HV: healthy volunteers; AON: APAP overdose patients with normal ALT; AOH: APAP 
overdose patients with high ALT. p-value shown in yellow is less than 0.05. 
 
C.3.2 Comparison of liver-specific cfDNA in clinical samples 
Data distribution of liver-specific cfDNA in clinical samples was 
analysed using a Shapiro-Wilk test. The null hypothesis of Shapiro-Wilk test is 
the data follow a normal distribution. The alternate hypothesis is the data do 
not follow a normal distribution. Shapiro-Wilk test showed p-value of 5.459 x 
10-7 (p-value < 0.05). Therefore, null hypothesis was rejected. The liver-
specific cfDNA data do not follow normal distribution. 
A non-parametric Mann-Whitney U test was used to analysed liver-
specific cfDNA between healthy volunteers (HV), APAP overdose patients with 
normal ALT (AON), and with high ALT (AOH) (Table C.3.2.1). A significant 
difference in median value of liver-specific cfDNA was observed between AOH 
and AON, as well as AOH and HV, but not between AON and HV. 
 
Table C.3.2.1 p-value from comparison of liver-specific cfDNA between clinical samples. 
p-value HV AON AOH 
HV NA 0.78 0.004 
AON 0.78 NA 0.03 
AOH 0.004 0.03 NA 
HV: healthy volunteers; AON: APAP overdose patients with normal ALT; AOH: APAP 




C.3.3 Associations of biomarkers in clinical samples 
Associations between total cfDNA and protein liver function biomarkers, 
as well as between liver-specific cfDNA and other liver function biomarkers 
were performed to compare the performance of total cfDNA and liver-specific 
cfDNA with protein liver function biomarkers, namely ALT and GLDH. 
A Spearman rho test was used for these association tests because both 
total cfDNA and liver-specific cfDNA do not follow normal data distribution (see 
section C.3.1 and C.3.2). A strong positive association was observed between 
total cfDNA and GLDH (p-value < 0.01). Positive association was observed 
between liver-specific cfDNA and ALT, as well as liver-specific cfDNA and 
GLDH (p-value < 0.05) (Table C.3.3.1). 
 
Table C.3.3.1 Spearman rho and p-value from analysis of associations between 
biomarkers in clinical samples. 
cfDNA analysis Liver protein biomarker Spearman rho p-value 
total cfDNA 
ALT 0.44 0.059 
GLDH 0.85 3.38 x 10-6 
liver-specific cfDNA 
ALT 0.57 0.01 
GLDH 0.59 0.01 
p-value shown in yellow is less than 0.05. 
